

ΒΙΟΓΡΑΦΙΚΟ ΣΗΜΕΙΩΜΑ

ΜΑΝΙΑΔΑΚΗΣ ΝΙΚΟΛΑΟΣ

**Καθηγητής Διοίκησης και Οργάνωσης Υπηρεσιών Υγείας
Αναπληρωτής Κοσμήτορας
Εθνική Σχολή Δημόσιας Υγείας
Λεωφόρος Αλεξάνδρας 196, Αθήνα 11521**

Email: *nmaniadakis@esdy.edu.gr*

Skype: *nikosmaniadakis*

Τηλ: *+306945237716*

Αθήνα, Οκτώβριος - 2017

ΠΕΡΙΕΧΟΜΕΝΑ

1. ΠΡΟΣΩΠΙΚΑ ΣΤΟΙΧΕΙΑ - ΕΚΠΑΙΔΕΥΣΗ	- 3 -
1.1 ΠΡΟΣΩΠΙΚΑ ΣΤΟΙΧΕΙΑ:.....	- 3 -
1.2 ΠΑΝΕΠΙΣΤΗΜΙΑΚΗ ΕΚΠΑΙΔΕΥΣΗ:.....	- 3 -
1.4 ΣΕΜΙΝΑΡΙΑ ΕΞΕΙΔΙΚΕΥΣΗΣ:	- 4 -
2. ΑΠΑΣΧΟΛΗΣΗ – ΔΙΟΙΚΗΤΙΚΗ ΕΜΠΕΙΡΙΑ	- 5 -
2.1 ΑΠΑΣΧΟΛΗΣΗ ΣΤΗΝ ΕΛΛΑΔΑ:	- 5 -
2.2 ΑΠΑΣΧΟΛΗΣΗ ΣΤΟ ΕΞΩΤΕΡΙΚΟ:	- 5 -
2.3 ΣΤΡΑΤΙΩΤΙΚΗ ΘΗΤΕΙΑ:.....	- 5 -
2.4 ΠΑΡΑΛΛΗΛΕΣ ΔΡΑΣΤΗΡΙΟΤΗΤΕΣ:	- 5 -
3. ΔΙΔΑΚΤΙΚΟ ΕΡΓΟ	- 6 -
3.1 ΑΥΤΟΝΟΜΗ ΔΙΔΑΣΚΑΛΙΑ ΣΕ ΜΕΤΑΠΤΥΧΙΑΚΑ ΠΡΟΓΡΑΜΜΑ ΣΠΟΥΔΩΝ:.....	- 6 -
3.2 ΔΙΑΛΕΞΕΙΣ ΣΕ ΜΕΤΑΠΤΥΧΙΑΚΑ ΠΡΟΓΡΑΜΜΑ ΣΠΟΥΔΩΝ:.....	- 6 -
3.3 ΑΥΤΟΝΟΜΗ ΔΙΔΑΣΚΑΛΙΑ ΣΕ ΠΡΟΠΤΥΧΙΑΚΑ ΠΡΟΓΡΑΜΜΑ ΣΠΟΥΔΩΝ:	- 7 -
3.5 ΣΥΝ-ΕΠΙΒΛΕΨΗ ΜΕΤΑΠΤΥΧΙΑΚΩΝ ΦΟΙΤΗΤΩΝ:	- 7 -
4. ΕΡΕΥΝΗΤΙΚΗ ΔΡΑΣΤΗΡΙΟΤΗΤΑ ΕΣΔΥ 2009 -.....	- 7 -
4.1 ΕΠΙΣΤΗΜΟΝΙΚΟΣ ΥΠΕΥΘΥΝΟΣ ΕΡΕΥΝΗΤΙΚΩΝ ΠΡΟΓΡΑΜΜΑΤΩΝ :.....	- 7 -
4.2 ΣΥΜΜΕΤΟΧΗ ΣΕ ΔΙΕΘΝΗ ΕΡΕΥΝΗΤΙΚΑ ΠΡΟΓΡΑΜΜΑΤΑ:	- 8 -
5. ΔΗΜΟΣΙΕΥΣΕΙΣ	- 8 -
5.1 ΣΥΜΜΕΤΟΧΗ ΣΤΗΝ ΕΚΔΟΤΙΚΗ ΟΜΑΔΑ:	- 8 -
5.2 ΔΗΜΟΣΙΕΥΣΕΙΣ ΣΕ ΠΕΡΙΟΔΙΚΑ ΜΕ ΑΞΙΟΛΟΓΗΣΗ: (112)	- 8 -
5.3 ΑΡΘΡΑ ΣΤΑ ΕΛΛΗΝΙΚΑ ΣΕ ΕΠΙΣΤΗΜΟΝΙΚΑ ΠΕΡΙΟΔΙΚΑ ΜΕ ΚΡΙΣΗ: (4)	- 20 -
5.4 ΜΟΝΟΓΡΑΦΙΕΣ ΣΤΑ ΑΓΓΛΙΚΑ ΣΕ ΔΙΕΘΝΕΙΣ ΣΕΙΡΕΣ ΜΕ ΚΡΙΣΗ: (7)	- 21 -
5.5 ΚΕΦΑΛΑΙΑ ΣΕ ΕΛΛΗΝΙΚΑ ΒΙΒΛΙΑ: (3).....	- 21 -
5.6 ΚΕΦΑΛΑΙΑ ΣΕ ΔΙΕΘΝΗ ΒΙΒΛΙΑ: (1).....	- 22 -
5.7 ΔΗΜΟΣΙΕΥΣΕΙΣ ΠΕΡΙΛΗΨΕΩΝ ΣΕ ΤΟΜΟΥΣ ΔΙΕΘΝΩΝ ΣΥΝΕΔΡΙΩΝ: (130).....	- 22 -
6. ΣΥΜΜΕΤΟΧΗ ΣΕ ΣΥΝΕΔΡΙΑ ΚΑΙ ΕΠΙΤΡΟΠΕΣ	- 33 -
6.1 ΜΕΛΟΣ ΣΕ ΕΠΙΤΡΟΠΕΣ ΕΜΠΕΙΡΟΓΝΩΜΟΝΩΝ:	- 33 -
6.2 ΣΥΜΜΕΤΟΧΗ ΣΕ ΣΥΝΕΔΡΙΑ: 2009 -	- 34 -

1. ΠΡΟΣΩΠΙΚΑ ΣΤΟΙΧΕΙΑ - ΕΚΠΑΙΔΕΥΣΗ

1.1 ΠΡΟΣΩΠΙΚΑ ΣΤΟΙΧΕΙΑ:

- ◆ Όνομα: Νικόλαος
- ◆ Επώνυμο: Μανιαδάκης
- ◆ Όνομα Πατρός: Γεώργιος
- ◆ Όνομα Μητρός: Ευθαλία
- ◆ Ημερομηνία Γέννησης: 9 Νοεμβρίου 1968
- ◆ Τόπος Γέννησης: Ιεράπετρα Κρήτης
- ◆ Υπηκοότητα : Ελληνική και Αγγλική
- ◆ Οικογενειακή Κατάσταση: Έγγαμος με δυο παιδιά
- ◆ Γλώσσες: Ελληνική, Αγγλική

1.2 ΠΑΝΕΠΙΣΤΗΜΙΑΚΗ ΕΚΠΑΙΔΕΥΣΗ:

- ◆ **Διδακτορικό στις Βιομηχανικές και Επιχειρησιακές Σπουδές (Ph.D in Industrial & Business Studies)**, 1995/96-1997/98, Σχολή Διοίκησης Γουόρικ (Warwick Business School), Πανεπιστήμιο Γουόρικ (University of Warwick), Κόβεντρυ, Ηνωμένο Βασίλειο.

Με υποτροφία του ΙΚΥ και του Βρετανικού Συμβουλίου.

Θέμα Διατριβής: «Ένας Malmquist Δείκτης Κόστους Εφαρμοσμένος Στην Μέτρηση της Παραγωγικότητας και της Οργάνωσης των Υπηρεσιών Υγείας»

- ◆ **Μάστερ στα Οικονομικά και τα Οικονομικά της Υγείας (M.Sc in Health Economics)**, 1994/95, Τμήμα Οικονομικών Σπουδών (Department of Economics), Πανεπιστήμιο Γιόρκ (University of York), Γιόρκ, Ηνωμένο Βασίλειο

Με υποτροφία του ΙΚΥ.

Θέμα Διατριβής: «Θεωρία και Εφαρμογές Μέτρησης της Παραγωγικότητας και Οργάνωσης των Υπηρεσιών Υγείας»

- ◆ **Πτυχίο Οικονομικών Σπουδών** (Λίαν Καλώς, ανώτατο 3%), 1986/97 – 1990/91, Τμήμα Οικονομικών Επιστημών, Σχολή Νομικών, Οικονομικών & Πολιτικών Επιστημών, Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών, Αθήνα, Ελλάδα.

1.3 ΣΧΟΛΙΚΗ ΕΚΠΑΙΔΕΥΣΗ:

- ◆ **Απολυτήριο Λυκείου** (Άριστα), 1983/84 -1985/86, 1ο Γενικό Λύκειο Ιεράπετρας, Λασιθι, Κρήτης

1.4 ΣΕΜΙΝΑΡΙΑ ΕΞΕΙΔΙΚΕΥΣΗΣ:

- ♦ **Εντατικό Σεμινάριο Οργάνωσης Υπηρεσιών Υγείας στην Βάση της Αξίας (Intensive Value Based Health Care Seminar), by Prof. M Porter, Σχολή Διοίκησης Πανεπιστημίου Χάρβαρντ (Harvard Business School), 4-8 Ιανουάριος 2016, Μασαχουσέτη, ΗΠΑ**
- ♦ **Σεμινάριο, για Ανώτατα Στελέχη, Καινοτομίας και Ηγεσίας για το Μέλλον των Υπηρεσιών Υγείας (Innovating Health for Tomorrow Executive Programme, Health Care Leadership), INSEAD, Ιανουάριος 26-30, Μάιος 5 2015, Φοτανεμπλώ, Γαλλία**

Με υποτροφία του INSEAD.

- ♦ **Σεμινάριο ΗΠΑ και Ευρώπης Καινοτομίας στην Πολιτική Υγείας (US European Health Policy Innovation Seminar, Transatlantic Health Policy) Πανεπιστήμιο Χάρβαρντ (Harvard University), Ιανουάριος 3-5 2011, Μασαχουσέτη, ΗΠΑ**

Με υποτροφία του Harvard.

- ♦ **Σεμινάριο Ηγεσίας και Συναισθηματικής Νοημοσύνης (Primal Leadership. Learning to Lead with Emotional Intelligence) by Dr. D. Coleman, Αθήνα 6 Ιουνίου 2006**
- ♦ **Σεμινάριο Διαχείρισης Αλλαγής (Leading Change. What Leader Do) by Dr. J. Kotter, Αθήνα 19 Οκτωβρίου 2005**
- ♦ **Δίπλωμα Ανεπτυγμένων Ποσοτικών Μεθόδων Φαρμακοοικονομικού Προγραμματισμού, 9 Νοεμβρίου 2003, Διεθνής Επιστημονική Εταιρεία Έρευνας στην Φαρμακοοικονομία και την Υγεία (International Society for Pharmacoeconomic and Outcomes Research), Βαρκελώνη, Ισπανία**
- ♦ **Δίπλωμα σε Ανεπτυγμένες Μεθόδους Αξιολόγησης Υπηρεσιών Υγείας, 9 -12 Δεκεμβρίου 2000, Ινστιτούτο Επιστημών Υγείας (Institute of Health Sciences), Πανεπιστήμιο της Οξφόρδης (University of Oxford), Οξφόρδη, Ηνωμένο Βασίλειο**
- ♦ **Δίπλωμα Επιχειρηματικής Εξειδίκευσης (Ανώτατο 5%), 21 Σεπτεμβρίου - 22 Δεκεμβρίου 1992, Τμήμα Οικονομικών Επιστημών Πανεπιστήμιο Αθηνών και Σχολή Διοίκησης, Πανεπιστήμιο Στέρλινγκ, Σκωτία**

Θέμα Διατριβής: «Ο Τομέας Υγείας στην Ελλάδα»

- ♦ **Magista Erasmus – Tempus Program Κοινωνική Ασφάλιση στην Ευρώπη (Διάκριση) (Certificate in Social Security Studies in Europe) 1990/91, Τμήμα Οικονομικών Επιστημών (Department of Economics), Πανεπιστήμιο Ροσκίλντε (Roskilde University), Ροσκίλντε, Δανία.**

Με υποτροφία του ΙΚΥ

Θέμα Διατριβής: «Η Παραοικονομία στην Παροχή Υπηρεσιών Υγείας»

2. ΑΠΑΣΧΟΛΗΣΗ – ΔΙΟΙΚΗΤΙΚΗ ΕΜΠΕΙΡΙΑ

2.1 ΑΠΑΣΧΟΛΗΣΗ ΣΤΗΝ ΕΛΛΑΔΑ:

- ♦ **Αναπληρωτής Κοσμήτορας**, 2013 – 2019, Εθνική Σχολή Δημόσιας Υγείας, Αθήνα
- ♦ **Καθηγητής και Διευθυντής Τομέα Οργάνωσης και Διοίκησης Υπηρεσιών Υγείας** 2009 – Σήμερα, Τομέας Οργάνωσης και Διοίκησης Υπηρεσιών Υγείας, Εθνική Σχολή Δημόσιας Υγείας, Αθήνα
- ♦ **Διοικητής & Πρόεδρος Διοικητικού Συμβουλίου**, 2004 – 2006, Πανεπιστημιακό Γενικό Νοσοκομείο Ηρακλείου, Βούτες, Ηρακλείου.
- ♦ **Διοικητής & Πρόεδρος Διοικητικού Συμβουλίου**, 2002 –2004, Πανεπιστημιακό Γενικό Νοσοκομείο Πατρών, Ρίο Πατρών.

2.2 ΑΠΑΣΧΟΛΗΣΗ ΣΤΟ ΕΞΩΤΕΡΙΚΟ:

- ♦ **Διευθυντής Ερευνητής Οικονομικών Υγείας (Senior Research Scientist of Health Economics)**, 2000 –2002, Ευρωπαϊκό Ερευνητικό Τμήμα Στρατηγικής Αγορών Υγείας (European Market Access Strategy Research), Διοίκηση Ευρώπης, Ερευνητικό Κέντρο Λίλλυ (European Headquarters, Lilly Research Centre), Eli Lilly & Co Ltd, Surrey, Ηνωμένο Βασίλειο
- ♦ **Διευθυντής Έρευνας Αποτελεσμάτων Υγείας (Manager Health Outcomes Research)** 1998 – 2000, Κέντρο Μελέτης Υπηρεσιών Υγείας Ευρώπης & Αφρικής (Health Services Research, Europe and Africa Area), Διοίκηση Ευρώπης και Αφρικής, Pharmacia Corp, High Wycombe, Ηνωμένο Βασίλειο
- ♦ **Ερευνητής Οικονομικών Υγείας (Assistant Research Fellow)**, 1996 –1998, Κέντρο Έρευνας Οικονομικών της Υγείας Ινστιτούτο Επιστημών Υγείας και Κολλέγιο Wolfson (Health Services Research Centre, Institute of Health Science), Πανεπιστήμιο της Οξφόρδης, Οξφόρδη, Ηνωμένο Βασίλειο.

2.3 ΣΤΡΑΤΙΩΤΙΚΗ ΘΗΤΕΙΑ:

- ♦ **Έφεδρος Αξιωματικός Οικονομικού, Προϊστάμενος Μηχανογράφησης Κεντρικού Ταμείου Στρατού**, Ιούνιος 1991 – Δεκέμβριος 1993, Κεντρικό Ταμείο Στρατού, Στρατιωτική Διοίκηση Αττικής, Υπουργείο Εθνικής Αμύνης, Αθήνα, Ελλάδα.

2.4 ΠΑΡΑΛΛΗΛΕΣ ΔΡΑΣΤΗΡΙΟΤΗΤΕΣ:

- ♦ **Επιστημονικός Συντονιστής**, 2010 – Σήμερα, Μονάδα Πολιτικής Υγείας, Ευρωπαϊκή Καρδιολογική Εταιρεία, Βρυξέλες, Βέλγιο
- ♦ **Διευθυντής ΜΠΣ στην Διοίκηση Υπηρεσιών Υγείας**, 2009-2017, Εθνική Σχολή Δημόσιας Υγείας
- ♦ **Συνεργαζόμενο Εκπαιδευτικό Προσωπικό**, 2008-2011, ΜΠΣ Διοίκησης Υπηρεσιών Υγείας, Ανοικτό Πανεπιστήμιο Κύπρου

- ◆ **Αμισθος Διευθύνων Σύμβουλος**, 2004-2006, Εταιρεία Διαχείρισης & Αξιοποίησης της Περιουσίας Πανεπιστημίου Κρήτης
- ◆ **Επισκέπτης Ερευνητής (Associate Fellow)**, 1998 – 2004, Κέντρο Σπουδών Υπηρεσιών Υγείας (Health Services Research Centre), Σχολή Διοίκησης Επιχειρήσεων (Warwick Business School), Πανεπιστήμιο Γουόρικ (University of Warwick), Κόβεντρι, Ηνωμένο Βασίλειο.
- ◆ **Διδάσκων με το Καθεστώς Νόμου 407**, 2002/03, Τμήμα Οικονομικών Επιστημών, Πανεπιστήμιο Πατρών, Πάτρα

3. ΔΙΔΑΚΤΙΚΟ ΕΡΓΟ

3.1 ΑΥΤΟΝΟΜΗ ΔΙΔΑΣΚΑΛΙΑ ΣΕ ΜΕΤΑΠΤΥΧΙΑΚΑ ΠΡΟΓΡΑΜΜΑ ΣΠΟΥΔΩΝ:

- ◆ **Αρχές Διοίκησης και Στρατηγικής Υπηρεσιών Υγείας**, 2009 – Σήμερα, ΜΠΣ Διοίκησης Υπηρεσιών Υγείας, Εθνική Σχολή Δημόσιας Υγείας, Αθήνα
- ◆ **Χρηματοοικονομική Ανάλυση και Διαχείριση Υπηρεσιών Υγείας**, 2008 – Σήμερα, ΜΠΣ Διοίκησης Υπηρεσιών Υγείας, Εθνική Σχολή Δημόσιας Υγείας, Αθήνα
- ◆ **Οικονομική και Χρηματοδοτική Διαχείριση Υπηρεσιών Υγείας**, 2007 – 2010, ΜΠΣ Διοίκησης Μονάδων Υγείας, Ανοικτό Πανεπιστήμιο Κύπρου, Λευκωσία, Κύπρος
- ◆ **Πολιτική Υγείας και Κοινωνικής Προστασίας Στην Ελλάδα και την ΕΕ**, 2005, ΜΠΣ Διοίκησης Υγείας, ΤΕΙ και Πανεπιστήμιο Πειραιώς, Αιγάλεω,
- ◆ **Επιχειρησιακή Στρατηγική**, 2005-2008, ΜΠΣ Διοίκησης Υγείας, ΤΕΙ και Πανεπιστήμιο Πειραιώς, Αιγάλεω,
- ◆ **Διοίκηση Υπηρεσιών Υγείας**, 2009, Μεταπτυχιακό Πρόγραμμα Σπουδών στο Φαρμακευτικό Μάρκετινγκ, Φαρμακευτική Σχολή, Πανεπιστήμιο Πάτρας, Πάτρα
- ◆ **Φαρμακοοικονομία**, 2005 - 2007, Μεταπτυχιακό Πρόγραμμα Σπουδών στο Φαρμακευτικό Μάρκετινγκ, Φαρμακευτική Σχολή, Πανεπιστήμιο Πάτρας, Πάτρα
- ◆ **Introduction to Mathematics**, 1996 – 1998, M.Sc. in Management Science and Operations Research, Warwick Business School, University of Warwick, United Kingdom

3.2 ΔΙΑΛΕΞΕΙΣ ΣΕ ΜΕΤΑΠΤΥΧΙΑΚΑ ΠΡΟΓΡΑΜΜΑ ΣΠΟΥΔΩΝ:

- ◆ **Economic Evaluation in Health Care**, 2016-17, Master of Science (MSc) in Health Economics, Outcomes and Management in Cardiovascular Sciences, London School of Economics,
- ◆ **Health Economics**, Diploma of Advanced Studies in Cardiac Arrhythmia Management (DAS-CAM), 2016 – 20017 Maastricht University, Netherlands

- ◆ **Μεθοδολογία Αξιολόγησης & Οργάνωσης Υπηρεσιών Υγείας**, 2004-2005, Μεταπτυχιακό Πρόγραμμα Σπουδών Δημόσια Υγεία και Διοίκηση Υπηρεσιών Υγείας, Ιατρική Σχολή, Πανεπιστήμιο Κρήτης, Ηράκλειο
- ◆ **Αξιολόγηση Υπηρεσιών Υγείας**, 2002, ΜΠΣ Διοίκησης Υπηρεσιών Υγείας, Εθνική Σχολή Δημόσιας Διοίκησης, Αθήνα
- ◆ **Health Technology Assessment**, 2002-2004, Πρόγραμμα Erasmus Αξιολόγησης Τεχνολογιών Υγείας, Ινστιτούτο Βιοιατρικής Τεχνολογίας, Πανεπιστήμιο Πατρών, Πάτρα
- ◆ **Seminar on Evaluation of Technologies**, 2000, Diploma/MSc in Regulatory Affairs, British Institute of Regulatory Affairs and University of Wales, 2001, Cardiff , Wales.

3.3 ΑΥΤΟΝΟΜΗ ΔΙΔΑΣΚΑΛΙΑ ΣΕ ΠΡΟΠΤΥΧΙΑΚΑ ΠΡΟΓΡΑΜΜΑ ΣΠΟΥΔΩΝ:

- ◆ **Οργάνωση και Διοίκηση Επιχειρήσεων**, 2002-2003, Πτυχίο Οικονομικών, Τμήμα Οικονομικών, Πανεπιστήμιο Πατρών, Πάτρα
- ◆ **Αξιολόγηση Επενδύσεων**, 2002-2003, Πτυχίο Οικονομικών, Τμήμα Οικονομικών, Πανεπιστήμιο Πατρών, Πάτρα.
- ◆ **Quantitative Methods in Economics and Management**, 1996 - 1998, B.Sc. in Management Science, Warwick Business School, University of Warwick, United Kingdom.

3.5 ΣΥΝ-ΕΠΙΒΛΕΨΗ ΜΕΤΑΠΤΥΧΙΑΚΩΝ ΦΟΙΤΗΤΩΝ:

- ◆ **Μάστερ:** ΜΠΣ Διοίκησης Υπηρεσιών Υγείας ΕΣΔΥ (11), ΜΠΣ Διοίκηση Υγείας Πανεπιστήμιο και ΤΕΙ Πειραιώς (5), M.Sc in Health Policy, London School of Economics (3), ΜΠΣ Πρόγραμμα Σπουδών Δημόσια Υγεία και Διοίκηση Υπηρεσιών Υγείας, Ιατρική Σχολή, Πανεπιστήμιο Κρήτης (2)
- ◆ **Διδακτορικό:** Ιατρική Σχολή Πανεπιστημίου Κρήτης (2), Νοσηλευτική Σχολή Πανεπιστημίου Αθήνας (3), Ιατρική Σχολή Πανεπιστημίου Αθήνας (1).

4. ΕΡΕΥΝΗΤΙΚΗ ΔΡΑΣΤΗΡΙΟΤΗΤΑ ΕΣΔΥ 2009 -

4.1 ΕΠΙΣΤΗΜΟΝΙΚΟΣ ΥΠΕΥΘΥΝΟΣ ΕΡΕΥΝΗΤΙΚΩΝ ΠΡΟΓΡΑΜΜΑΤΩΝ :

- ◆ **Ιδιωτική χρηματοδότηση:** συνολικά 62 έργα προϋπολογισμού € 4.9 εκατομμύριων σε θέματα οικονομική αξιολόγησης, πολιτικής και διοίκησης υπηρεσιών υγείας.
- ◆ **Δημόσια χρηματοδότηση:** συνολικά από ΕΣΠΑ 3 έργα € 3.6 Εκατομμυρίων Ευρώ σε θέματα οργάνωση, πολιτική και διοίκησης υπηρεσιών υγείας
- ◆ **Επιλεγμένα έργα και μελέτες Εθνικού βεληνεκούς:** α.) Μελέτη και εφαρμογή των DRGs για την αποζημίωση των νοσοκομείων στην Ελλάδα (2011), β.) Μελέτη και εφαρμογή για την χρήση αναλυτικής λογιστικής και διπλογραφικού στα δημόσια νοσοκομεία (2011). γ.) Μέτρηση και ανάλυση παραγωγικότητας των νοσοκομείων του ΕΣΥ (2010), δ.) Μέτρηση εθνικού κόστους αθηροσκλήρωσης, άσθματος, χρόνιας αποφρακτικής πνευμονοπάθειας.

4.2 ΣΥΜΜΕΤΟΧΗ ΣΕ ΔΙΕΘΝΗ ΕΡΕΥΝΗΤΙΚΑ ΠΡΟΓΡΑΜΜΑΤΑ:

- ◆ **BigData&Heart (2017-2022)**, Work Package 3 Co-Leader of IMI2, undertaken by several academic and industry partners including Harvard-Karolinska-BCG ICHOM, UCL, Cambridge, ESC, Utrecht and other universities. Funded by EU and EFPIA with 20 million.
- ◆ **European Atlas of Cardiology (2010-2018)** designed and completed the ESC European Atlas of cardiology for 56 countries; Funded by the European Society of Cardiology.
- ◆ **CATH ME (Characterizing Atrial Fibrillation by Translating its caused into health modifies in the Elderly (2015-2019))**. Responsible for health economics and policy module. A Horizon 2020 project. Funded by EU with 5 million.

5. ΔΗΜΟΣΙΕΥΣΕΙΣ

5.1 ΣΥΜΜΕΤΟΧΗ ΣΤΗΝ ΕΚΔΟΤΙΚΗ ΟΜΑΔΑ:

- ◆ **Associate Editor:** Applied Health Economics and Policy, <https://link.springer.com/journal/40258>
- ◆ **Editorial Board Member:** PharmacoEconomics, <https://link.springer.com/journal/40273>
- ◆ **Referee:** Applied Economics, Health Economics, Medical Economics, Pharmacoeconomics, Applied Health Economics and Policy, Health Economics and Policy Review, European Journal of Health Economics, Social Science, Clinical Economics and Outcomes Research, European Journal of Operational Research, Journal of Health Care Management Science, Journal of the Operational Research Society, Operational Research: an International Journal, Journal of Productivity Analysis, Journal of Performance Management, Journal of Outcomes and Disease Management, International Journal of Outcomes Research, Drug, Drug Therapy, British Journal of Clinical Oncology, Therapeutics and Clinical Research, Pain, Outcomes Research, Pharmacology, Diabetic Medicine, Cancer Treatments Reviews, Breast Cancer, British Journal of Cancer, Oncology, Lung Cancer, Acta Oncologica, BMJ, Pharmacology, Breast, Lancet, JAMA.

5.2 ΔΗΜΟΣΙΕΥΣΕΙΣ ΣΕ ΠΕΡΙΟΔΙΚΑ ΜΕ ΑΞΙΟΛΟΓΗΣΗ: (112)

- ◆ **Άρθρα:** 122
- ◆ **Αναφορές (citations):** 3844
- ◆ **Συντελεστής Επίπτωσης (impact factor):** 709
- ◆ **H index:** 24

- ◆ Van Hagen I, Hall R, Baart S, Maggioni A, Tavazzi L, Bartolomei B, Lelonek M, Johnson M, Maniadakis N, et al. Influence of socioeconomic factors on pregnancy outcome in women with structural heart disease. Heart (accepted)
Impact Factor: 6.059, Citations: .
- ◆ Timmis A, Townsend N, Gale C, Grobbee D, Maniadakis N, Flather M, Wilkins E, Wright F, Vos R, Bax J, Blum M, Pinto F, Vardas P. European Society of Cardiology: Cardiovascular Disease Statistics 2017. European Heart Journal, 2017
Impact Factor: 20.213, Citations: .

- ◆ Hemingway H, Asselbergs F, Danesh F, Dobson R, Maniadakis N, et al. Big data from electronic health records for early and late translational cardiovascular research: challenges and potential European Heart Journal, 2017, ehx487, <https://doi.org/10.1093/eurheartj/ehx487>
Impact Factor: 20.213, Citations: .
- ◆ Brixner D, Maniadakis N, Kaló Z, Hu S, Shen J, Wijaya K. Considering Multicriteria Decision Analysis (MCDA) Simple Scoring as an Evidence-Based HTA Methodology for Evaluating Off-Patent Pharmaceuticals (OPPs) in Emerging Markets, Value in Health Regional Issues, 2017, 13, 1–6
- ◆ Tzanetakos C, Tzioufas A, Goules A, Kourlaba G, Theodoratou T, Christou P, Maniadakis N. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece. Rheumatol Int. 2017 May 18. doi: 10.1007/s00296-017-3736-z. [Epub ahead of print]
Impact Factor: 1.824, Citations: .
- ◆ Gourzoulidis G, Kourlaba G, Kakisis J, Matsagkas M, Giannakoulas G, Gourgoulisanis KI, Vassilakopoulos T, Maniadakis N. Cost-Effectiveness Analysis of Rivaroxaban for Treatment of Deep Vein Thrombosis and Pulmonary Embolism in Greece. Clin Drug Investig. 2017 Jun 12. doi: 10.1007/s40261-017-0540-1. [Epub ahead of print]
Impact Factor: 1.853, Citations: .
- ◆ Fragoulakis V, Mitropoulou C, Katelidou D, van Schaik RH, Maniadakis N, Patrinos GP. Performance Ratio Based Resource Allocation Decision-Making in Genomic Medicine. OMICS. 2017 Feb;21(2):67-73. doi: 10.1089/omi.2016.0161. Epub 2017 Jan 24.
Impact Factor: 1.723 Citations: .
- ◆ Maniadakis N, Kourlaba G, Shen J, Holtorf, A. Comprehensive taxonomy and worldwide trends in pharmaceutical policies in relation to country income status." BMC Health Serv Res, 2017, 17(1): 371.
Impact Factor: 1.827, Citations: .
- ◆ Stafylas P, Farmakis D, Kourlaba G, Giamouzis G, Tsarouhas K, Maniadakis N, Parissis J. The heart failure pandemic: The clinical and economic burden in Greece. Int J Cardiol, 2017; 227, 923-929.
Impact Factor: 6.189, Citations: .
- ◆ Farmakis D, Stafylas P, Giamouzis G, Maniadakis N, Parissis J. The medical and socioeconomic burden of heart failure: A comparative delineation with cancer International Journal of Cardiology 203 (2016) 279–281
Impact Factor: 6.189, Citations: .
- ◆ Gourzoulidis, G., Kourlaba, G. Stafylas, P. Giamouzis, G. Parissis, J. Maniadakis, N. Association between copayment, medication adherence and outcomes in the management of patients with diabetes and heart failure. Health Policy, 2017. 121(4): p. 363-377.
Impact Factor: 2.119, Citations: .
- ◆ Fragoulakis V, Mitropoulou C, Katelidou D, van Schaik, RH, Maniadakis N, Patrinos G. Performance Ratio Based Resource Allocation Decision-Making in Genomic Medicine. OMICS, 2017. 21(2): p. 67-73.
Impact Factor: 2.723, Citations: .

- ◆ Kourlaba G, Gialama F, Tsioufis K, Maniadakis N. A literature review to evaluate the clinical and economic value of olmesartan for the treatment of hypertensive patients. *Int J Cardiol*. 2016 Jun 24;221:60-74. doi: 10.1016/j.ijcard.2016.06.115. [Epub ahead of print]
Impact Factor: 6.189, Citations: 3.
- ◆ Kourlaba G, Hillas G, Vassilakopoulos T, Maniadakis N. The disease burden of chronic obstructive pulmonary disease in Greece. *Int J Chron Obstruct Pulmon Dis*. 2016 Sep 9;11:2179-2189. eCollection 2016.
Impact Factor: 3.157, Citations: 3.
- ◆ Fragoulakis V, Pescott CP, Smeenk JM, van Santbrink EJ, Oosterhuis GJ, Broekmans FJ, Maniadakis N Economic Evaluation of Three Frequently Used Gonadotrophins in Assisted Reproduction Techniques in the Management of Infertility in the Netherlands. *Appl Health Econ Health Policy*. 14(6): p. 719-727.
Impact Factor: 2.06, Citations: 1.
- ◆ Tzanetakos C, Tentolouris N, Kourlaba G, Maniadakis N. Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece. *Clin Drug Investig*. 2016 Aug;36(8):649-59. doi: 10.1007/s40261-016-0410-2.
Impact Factor: 1.853, Citations: 3.
- ◆ Body JJ, Acklin YP, Gunther O, Hechmati G, Pereira J, Maniadakis N, Terpos E, Finek J, von Moos R, Talbot S, Sleeboom H. Pathologic fracture and healthcare resource utilisation: A retrospective study in eight European countries. *J Bone Oncol*, 2016. 5(4): p. 185-193.
Impact Factor: 0.947, Citations: .
- ◆ Fragoulakis V, Mitropoulou C, van Schaik RH, Maniadakis N, Patrinos GP. An Alternative Methodological Approach for Cost-Effectiveness Analysis and Decision Making in Genomic Medicine. *OMICS*. 2016 May;20(5):274-82. doi: 10.1089/omi.2016.0018. Epub 2016 Apr 20.
Impact Factor: 2.723, Citations: 2.
- ◆ Kourlaba G, Relakis J, Mahon R, Kalogeropoulou M, Pantelopoulou G, Kousidou O, Maniadakis N. Cost-utility of ranibizumab versus aflibercept for treating Greek patients with visual impairment due to diabetic macular edema. *Cost Eff Resour Alloc*. 2016 Apr 14;14:7. doi: 10.1186/s12962-016-0056-
Impact Factor: 1.76, Citations: 3.
- ◆ Vellopoulou K, Kourlaba G, Maniadakis N, Vardas P. A literature review to evaluate the economic value of ranolazine for the symptomatic treatment of chronic angina pectoris. *Int J Cardiol*. 2016 May 15;211:105-11. doi: 10.1016/j.ijcard.2016.02.140. Epub 2016 Mar 2. Review.
Impact Factor: 6.189, Citations: 1.
- ◆ Fanourgiakis J, Simantirakis E, Maniadakis N, Kanoupakis E, Chrysostomakis S, Kourlaba G, Chlouverakis G, Vardas P. Complications Related to Cardiac Rhythm Management Device Therapy and Their Financial Implication: A Prospective Single-Center TwoYear Survey. *Hellenic J Cardiol*. 2016 Jan-Feb;57(1):33-8.
Impact Factor: 1.343, Citations: 7.

- ◆ Pereira J, Body JJ, Gunther O, Sleeboom H, Hechmati G, Maniadakis N, Terpos E, Acklin YP, Finek J, von Moos R. Cost of skeletal complications from bone metastases in six European countries. *J Med Econ*. 2016 Jun;19(6):611-8. doi: 10.3111/13696998.2016.1150852. Epub 2016 Feb 23.
Impact Factor: -, Citations: 7.
- ◆ Fabritz L, Guasch E, Antoniadou C, Bardinet I, Benninger G, Betts TR, Brand E, Breithardt G, Bucklar-Suchankova G, Camm AJ, Cartlidge D, Casadei B, Chua WW, Crijns HJ, Deeks J, Hatem S, Hidden-Lucet F, Kääh S, Maniadakis N, Martin S, Mont L, Reinecke H, Sinner MF, Schotten U, Southwood T, Stoll M, Vardas P, Wakili R, West A, Ziegler A, Kirchhof P. Expert consensus document: Defining the major health modifiers causing atrial fibrillation: a roadmap to underpin personalized prevention and treatment. *Nat Rev Cardiol*. 2016 Apr;13(4):230-7. doi: 10.1038/nrcardio.2015.194. Epub 2015 Dec
Impact Factor: 14.299, Citations: 33.
- ◆ Maggioni AP, Van Gool K, Biondi N, Urso R, Klazinga N, Ferrari R, Maniadakis N, Tavazzi L. Appropriateness of Prescriptions of Recommended Treatments in Organisation for Economic Co-operation and Development Health Systems: Findings Based on the Long-Term Registry of the European Society of Cardiology on Heart Failure. *Value Health*. 2015 Dec;18(8):1098-104. doi: 10.1016/j.jval.2015.08.005. Epub 2015 Sep 14.
Impact Factor: 4.235, Citations: 4.
- ◆ Kourlaba G, Vlachopoulos C, Parissis J, Kanakakis J, Gourzoulidis G, Maniadakis N. Ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Greece: a cost-utility study. *BMC Health Serv Res*. 2015 Dec 18;15:566. doi: 10.1186/s12913-015-1228-y.
Impact Factor: 1.827, Citations: 2.
- ◆ Farmakis D, Stafylas P, Giamouzis G, Maniadakis N, Parissis J. The medical and socioeconomic burden of heart failure: A comparative delineation with cancer. *Int J Cardiol*. 2016 Jan 15;203:279-81. doi: 10.1016/j.ijcard.2015.10.172. Epub 2015 Oct 20.
Impact Factor: 6.189, Citations: 14.
- ◆ Thanassoulis, E., Shiraz R, Maniadakis N, A cost Malmquist productivity index capturing group performance. *European J Operations Research* 2015 241: p. 796-805.
Impact Factor: 3.297, Citations: 15.
- ◆ Kourlaba G, Relakis J, Kontodimas S, Holm MV, Maniadakis N. A systematic review and meta-analysis of the epidemiology and burden of venous thromboembolism among pregnant women. *Int J Gynaecol Obstet*. 2016 Jan;132(1):4-10. doi: 10.1016/j.ijgo.2015.06.054. Epub 2015 Oct 9.
Impact Factor: 2.174, Citations: 19.
- ◆ Kourlaba G, Gourzoulidis G, Andrikopoulos G, Tsioufis K, Beletsi A, Maniadakis N. Economic evaluation of trimetazidine in the management of chronic stable angina in Greece. *BMC Health Services*, (2016) 16:520 DOI 10.1186/s12913-016-1779-6
Impact Factor: 1.827, Citations: 2.
- ◆ Body JJ, Pereira J, Sleeboom H, Maniadakis N, Terpos E, Acklin YP, Finek J, Gunther O, Hechmati G, Mossman T, Costa L, Rogowski W, Nahi H, von Moos R. Health resource utilization associated with skeletal-related events: results from a retrospective European study. *Eur J Health Econ*. 2016 Jul;17(6):711-21. doi: 10.1007/s10198-015-0716-7. Epub 2015 Aug 8.
Impact Factor: 2.50, Citations: 4.

- ◆ Kourlaba G, Rapti V, Alexopoulos A, Relakis J, Koumakis G, Chatzikou M, Maniadakis N, Georgoulas V. Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation study. BMC Health Serv Res. 2015 Aug 5;15:307. doi: 10.1186/s12913-015-0971-4.
Impact Factor: 1.827, Citations: 3.
- ◆ Vardas P, Maniadakis N, Bardinet I, Pinto F. The European Society of Cardiology Atlas of Cardiology: rational, objectives, and methods. European Heart Journal – Quality of Care and Clinical Outcomes doi:10.1093/ehjqcco/qcv020
Factor: , Citations: 7.
- ◆ Stafylas P, Kourlaba G, Hatzikou M, Georgiopoulos D, Sarafidis P, Maniadakis N. Economic evaluation of a single-pill triple antihypertensive therapy with valsartan, amlodipine, and hydrochlorothiazide against its dual components. Cost Eff Resour Alloc 2015;13:10.
Impact Factor: 1.76, Citations: 2.
- ◆ Plagisou L, Tsironi M, Zyga S, Moisoglou I, Maniadakis N, Prezerakos P. Assessment of nursing staff's theoretical knowledge of cardiovascular resuscitation in an NHS public hospital. Hellenic J Cardiol 2015;56(2):149-53.
Impact Factor: 1.343, Citations: 9.
- ◆ Kourlaba G, Relakis J, Mylonas C, Kapaki V, Kontodimas S, Holm MV, et al. The humanistic and economic burden of venous thromboembolism in cancer patients: a systematic review. Blood Coagul Fibrinolysis 2015;26(1):13-31.
Impact Factor: 1.367, Citations: 12.
- ◆ Maniadakis N, Fragoulakis V, Mylonas C, Sharma R, Coats A. Economic evaluation of Cardiac Contractility Modulation (CCM) therapy with the optimizer IVs in the management of heart failure patients International Cardiovascular Forum Journal 4 (2015), DOI: 10.17987/icfj.v4i0.173
- ◆ Kourlaba G, Dimopoulos MA, Pectasides D, Skarlos DV, Gogas H, Pentheroudakis G, et al. Comparison of filgrastim and pegfilgrastim to prevent neutropenia and maintain dose intensity of adjuvant chemotherapy in patients with st cancer. Support Care Cancer 2015;23(7):2045-51.
Impact Factor: 2.698, Citations: 3.
- ◆ Fragoulakis V, Vitsou E, Hernandez AC, Maniadakis N. Economic evaluation of anti-TNF agents for patients with rheumatoid arthritis in Greece. Clinicoecon Outcomes Res 2015;7:85-93.
Impact Factor: 2.48, Citations: .
- ◆ Fragoulakis V, Raptis E, Vitsou E, Maniadakis N. Annual biologic treatment cost for new and existing patients with moderate to severe plaque psoriasis in Greece. Clinicoecon Outcomes Res 2015;7:73-83.
Impact Factor: 2.48, Citations: 2.
- ◆ Moisoglou I, Prezerakos P, Galanis P, Siskou O, Maniadakis N, Kaitelidou D, Conflict Management in a Greek Public Hospital: Collaboration or Avoidance? International Journal of Caring Sciences, 2014, 7, 75-82
- ◆ Dreliozi A, Siskou O, Maniadakis N, Prezerakos P. Continuing Education and Development Opportunities in Greek Hospitals: Comparison of Perspectives between Nurses and other Health

Professionals. *International Journal Of Occupational Health and Public Health Nursing*, vol.1, no. 2, 2014, 3-16

- ◆ Tzanetakos C, Melidonis A, Verras C, Kourlaba G, Maniadakis N. Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece. *BMC Health Serv Res* 2014;14:419.
Impact Factor: 1.827, Citations: 10.
- ◆ Gialama F, Miloni E, Maniadakis N. Cost Effectiveness of Treatments for non-ST-segment elevation Acute Coronary Syndrome. *Pharmacoeconomics* 2014.
Impact Factor: 3.63, Citations: 1.
- ◆ Fragoulakis V, Stamoulis K, Grouzi E, Maniadakis N. The cost of blood collection in Greece: an economic analysis. *Clin Ther* 2014;36(7):1028-1036 e5.
Impact Factor: 2.947, Citations: 4.
- ◆ Kourlaba G, Maniadakis N, Andrikopoulos G, Vardas P. Economic evaluation of rivaroxaban in stroke prevention for patients with atrial fibrillation in Greece. *Cost Eff Resour Alloc* 2014;12(1):5.
Impact Factor: 1.76, Citations: 12.
- ◆ Gialama F, Prezerakos P, Maniadakis N. The cost effectiveness of implantable cardioverter defibrillators: a systematic review of economic evaluations. *Appl Health Econ Health Policy* 2014;12(1):41-9.
Impact Factor: 2.06, Citations: 5.
- ◆ Kourlaba G1, Parissis J, Karavidas A, Beletsi A, Milonas C, Branscombe N, Maniadakis N. Economic evaluation of ivabradine in the treatment of chronic heart failure in Greece. *BMC Health Serv Res*. 2014 Dec 11;14:631. doi: 10.1186/s12913-014-0631-0.
Impact Factor: 1.827, Citations: 8.
- ◆ Maniadakis N, Kapaki V, Damianidi L, Kourlaba G. A systematic review of the effectiveness of taxes on nonalcoholic beverages and high-in-fat foods as a means to prevent obesity trends. *Clinicoecon Outcomes Res*. 2013 Oct 22;5:519-543. Review.
Impact Factor: 2.48, Citations: 21.
- ◆ Charalambous C, Maniadakis N, Polyzos N, Fragoulakis V, Theodorou M. The efficiency of the public dental services (PDS) in Cyprus and selected determinants. *BMC Health Serv Res*. 2013 Oct 18;13(1):420. [Epub ahead of print]
Impact Factor: 1.827, Citations: 6.
- ◆ Gialama F, Maniadakis N. Comprehensive overview: efficacy, tolerability, and cost-effectiveness of irbesartan. *Vasc Health Risk Manag*. 2013;9:575-92. doi: 10.2147/VHRM.S50831. Epub 2013 Oct 7. Review.
Impact Factor: 2.94, Citations: 5.
- ◆ Anastasiadis K, Fragoulakis V, Antonitsis P, Maniadakis N. Coronary artery bypass grafting with minimal versus conventional extracorporeal circulation; an economic analysis. *Int J Cardiol*. 2013 Oct 15;168(6):5336-43. doi: 10.1016/j.ijcard.2013.08.006. Epub 2013 Aug 15.
Impact Factor: 6.189, Citations: 16.

- ◆ Andrikopoulos GK, Fragoulakis V, Maniadakis N. Economic evaluation of dabigatran etexilate in the management of atrial fibrillation in Greece. *Hellenic J Cardiol*. 2013 Jul-Aug;54(4):289-300. Impact Factor: 1.343, Citations: 5.
- ◆ Fragoulakis V, Maniadakis N. Estimating the long-term effects of in vitro fertilization in Greece: an analysis based on a lifetime-investment model. *Clinicoecon Outcomes Res*. 2013 Jun 20;5:247-55. doi: 10.2147/CEOR.S44784. Print 2013. Impact Factor: 2.48, Citations: 3.
- ◆ Dreliozi A, Siskou O, Maniadakis N, Prezerakos P. Clinical Governance and Effective Quality & Risk Management in Greek Hospitals *International Journal of Health Research and Innovation*, vol. 1, no. 3, 2013, 7-17 ISSN: 2051-5057 (print version), 2051-5065 (online)
- ◆ Kourlaba G, Fragoulakis V, Theodoratou D, Maniadakis N. Economic evaluation of telmisartan, valsartan and losartan in combination with hydrochlorothiazide for treatment of mild-to-moderate hypertension in Greece: a cost-utility analysis. *Journal of Pharmaceutical Health Services Research*. 2013, 4(2), 81–88
- ◆ Maniadakis N, Kourlaba G, Mouggiakos T, Chatzimanolis I, Jonsson L. Economic evaluation of agomelatine relative to other antidepressants for treatment of major depressive disorders in Greece. *BMC Health Serv Res*. 2013 May 10;13(1):173. [Epub ahead of print] Impact Factor: 1.827, Citations: 5.
- ◆ Fragoulakis V, Kastritis E, Psaltopoulou T, Maniadakis N. Economic evaluation of therapies for patients suffering from relapsed-refractory multiple myeloma in Greece. *Cancer Manag Res*. 2013 Apr 10;5:37-48. doi: 10.2147/CMAR.S43373. Print 2013. Impact Factor: 4.79, Citations: 8.
- ◆ Boriani G, Maniadakis N, Auricchio A, Müller-Riemenschneider F, Fattore G, Leyva F, Mantovani L, Siebert M, Willich SN, Vardas P, Kirchhof P. Health technology assessment in interventional electrophysiology and device therapy: a position paper of the European Heart Rhythm Association. *Eur Heart J*. 2013 Feb 7. [Epub ahead of print] Impact Factor: 20.213, Citations: 36.
- ◆ Theodorou M, Stafylas P, Kourlaba G, Kaitelidou D, Maniadakis N, Papademetriou V. Physicians' perceptions and adherence to guidelines for the management of hypertension: a national, multicentre, prospective study. *Int J Hypertens*. 2012;2012:503821. doi: 10.1155/2012/503821. Epub 2012 Nov 28. Impact Factor: 2.16, Citations: 14.
- ◆ Fanourgiakis J, Simantirakis E, Maniadakis N, Kourlaba G, Kanoupakis E, Chrysostomakis S, Vardas P. Cost-of-illness study of patients subjected to cardiac rhythm management devices implantation: results from a single tertiary centre. *Europace*. 2013 Mar;15(3):366-75. doi: 10.1093/europace/eus363. Epub 2012 Nov 12. Impact Factor: 2.94, Citations: 9.
- ◆ Panagopoulou P, Gogas H, Dessypris N, Maniadakis N, Fountzilias G, Petridou ET. Survival from breast cancer in relation to access to tertiary healthcare, body mass index, tumor characteristics and treatment: a Hellenic Cooperative Oncology Group (HeCOG) study. *Eur J Epidemiol*. 2012 Oct 20. [Epub ahead of print] Impact Factor: 3.73, Citations: 15.

- ◆ Fragoulakis V, Papagiannopoulou V, Kourlaba G, Maniadakis N, Fountzilas G. Cost-minimization analysis of the treatment of patients with metastatic colorectal cancer in Greece. *Clin Ther.* 2012 Oct;34(10):2132-42. doi: 10.1016/j.clinthera.2012.09.005. Impact Factor: 2.947, Citations: 6.
- ◆ Fragoulakis V, Kourlaba G, Tarlatzis B, Mastrominas M, Maniadakis N. Economic evaluation of alternative assisted reproduction techniques in management of infertility in Greece. *Clinicoecon Outcomes Res.* 2012;4:185-92. Epub 2012 Jul 12. Impact Factor: 2.48, Citations: 5.
- ◆ Kourlaba G, Fragoulakis V, Maniadakis N. Clopidogrel versus aspirin in patients with atherothrombosis: a CAPRIE-based cost-effectiveness model for Greece. *Appl Health Econ Health Policy.* 2012 Sep 1;10(5):331-42. doi: 10.2165/11633970-000000000-00000. Impact Factor: 2.06, Citations: 5.
- ◆ Maniadakis N, Kourlaba G, Cokkinos DV, Angeli A, Kyriopoulos J. The economic burden of atherothrombosis in Greece: results from the THESIS study. *Eur J Health Econ.* 2012 Jul 10. Impact Factor: 2.500, Citations: 5.
- ◆ Fragoulakis V, Kourlaba G, Maniadakis N. Economic evaluation of statins in high-risk patients treated for primary and secondary prevention of cardiovascular disease in Greece. *Clinicoecon Outcomes Res.* 2012;4:135-43. Epub 2012 May 29. Impact Factor: 2.48, Citations: 11.
- ◆ Fragoulakis V, Pallis A, Kaitelidou D, Maniadakis N, Georgoulas V. Economic evaluation of pemetrexed versus erlotinib as second-line treatment of patients with advanced/metastatic non-small cell lung cancer in Greece: a cost minimization analysis. *Lung Cancer (Auckl).* 2012 Jul 16;3:43-51. doi: 10.2147/LCTT.S33608. eCollection 2012. Impact Factor: 4.294 , Citations: 2.
- ◆ Kourlaba G, Fragoulakis V, Maniadakis N. Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis. *Appl Health Econ Health Policy.* 2012 Jul 1;10(4):261-71. doi: 10.2165/11633820-000000000-00000. Impact Factor: 2.06, Citations: 7.
- ◆ Fragoulakis V, Kourlaba G, Goumenos D, Konstantoulakis M, Maniadakis N. Economic evaluation of intravenous iron treatments in the management of anemia patients in Greece. *Clinicoecon Outcomes Res.* 2012;4:127-34. Epub 2012 May 4. Impact Factor: 2.48, Citations: 22.
- ◆ Athanasakis K, Fragoulakis V, Tsiantou V, Masaoutis P, Maniadakis N, Kyriopoulos J. Cost-Effectiveness Analysis of Ranibizumab versus Verteporfin Photodynamic Therapy, egaptanib Sodium, and Best Supportive Care for the Treatment of Age-Related Macular Degeneration in Greece. *Clin Ther.* 2012 Feb;34(2):446-56. Epub 2012 Jan 30. Impact Factor: 2.947, Citations: 11.
- ◆ Liatsikos E, Kyriazis I, Kallidonis P, Sakellaropoulos G, Maniadakis N .Photoselective GreenLight™ Laser Vaporization Versus Transurethral Resection of the Prostate in Greece: A Comparative Cost Analysis. *J Endourol.* 2012 Feb;26(2):168-73. Epub 2011 Nov 11. Impact Factor: 2.27, Citations: 20.

- ◆ Theodorou M, Kaitelidou D, Galanis P, Middleton N, Theodorou P, Stafylas P, Siskou O, Maniadakis N. Quality of life measurement in patients with hypertension in Cyprus. *Hellenic J Cardiol*. 2011 Sep-Oct;52(5):407-15.
Impact Factor: 1.343, Citations: 32.
- ◆ Maniadakis N, Ekman M, Calvert MJ, Freemantle N, Karamalis M, Vardas P. Cost effectiveness of cardiac resynchronization therapy in Greece: an analysis based on the CARDiac REsynchronization in Heart Failure trial. *Europace*. 2011 Nov;13(11):1597-603. Epub 2011 Aug 6.
Impact Factor: 2.94, Citations: 7.
- ◆ Boriani G, Burri H, Mantovani LG, Maniadakis N, Leyva F, Kautzner J, Lubinski A, Braunschweig F, Jung W, Lozano IF, Fattore G. Device therapy and hospital reimbursement practices across European countries: a heterogeneous scenario. *Europace*. 2011 May;13 Suppl 2:ii59-65.
Impact Factor: 2.94, Citations: 29.
- ◆ Fattore G, Maniadakis N, Mantovani LG, Boriani G. Health technology assessment: what is it? Current status and perspectives in the field of electrophysiology. *Europace*. 2011 May;13 Suppl 2:ii49-53.
Impact Factor: 2.94, Citations: 3.
- ◆ Kautzner J, Bulkova V, Hindricks G, Maniadakis N, Della Bella P, Jais P, Kuck KH. Atrial fibrillation ablation: a cost or an investment? *Europace*. 2011 May;13 Suppl 2:ii39-43.
Impact Factor: 2.94, Citations: 5.
- ◆ Maniadakis N, Vardas P, Mantovani LG, Fattore G, Boriani G. Economic evaluation in cardiology. *Europace*. 2011 May;13 Suppl 2:ii3-8.
Impact Factor: 2.94, Citations: 22.
- ◆ Maniadakis N, Kourlaba G, Fragoulakis V. Self-reported prevalence of atherothrombosis in a general population sample of adults in Greece; a telephone survey. *BMC Cardiovasc Disord*. 2011 Apr 14;11:16.
Impact Factor: 2.32, Citations: 7.
- ◆ Pallis A1, Tsiantou V, Simou E, Maniadakis N. Pharmacoeconomic considerations in the treatment of breast cancer. *Clinicoecon Outcomes Res*. 2010;2:47-61. Epub 2010 Jun 15.
Impact Factor: 2.48, Citations: 12.
- ◆ Simou E, Tsimitselis D, Tsopanlioti M, Anastasakis I, Papatheodorou D, Kourlaba G, Gerasimos P, Maniadakis N. Early evaluation of an organised mammography screening program in Greece 2004-2009. *Cancer Epidemiol*. 2011 Apr 5. [Epub ahead of print]
Impact Factor: 2.343, Citations: 4.
- ◆ Maniadakis N, Ekman M, Fragoulakis V, Papagiannopoulou V, Yfantopoulos J. Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece. *Eur J Health Econ*. 2011 Jun;12(3):253-61. Epub 2010 Apr 22.
Impact Factor: 2.500, Citations: 12.
- ◆ Maniadakis N, Fragoulakis V, Pallis A, Simou E, V Georgoulis. Economic Evaluation Docetaxel/Gemcitabine versus Vinorelbine/ Cisplatin combination as Front-line Treatment for Patients with Advanced/Metastatic Non Small Cell Lung Cancer in Greece: A cost minimization analysis. *Ann Oncol*. 2010 Jul;21(7):1462-7. Epub 2009 Dec 17.

Impact Factor: 11.855, Citations: 13.

- ◆ Boriani G, Maniadakis N, Auricchio A, Vardas P. Health economics and outcomes research: a new challenge and field of action for the European Heart Rhythm Association. *Europace*. 2010 May;12(5):601-3. Epub 2010 Mar 10.
Impact Factor: 2.94, Citations: 19.
- ◆ Simou E, Foundoulakis E, Kourlaba G, Maniadakis N. Factors associated with the use of preventive services by women in Greece. *Eur J Public Health*. 2010 Jul 22. [Epub ahead of print]
Impact Factor: 2.27, Citations: 10.
- ◆ Simou E, Maniadakis N, Pallis A, Foundoulakis E, Kourlaba G. Factors associated with the use of pap smear testing in Greece. *J Womens Health (Larchmt)*. 2010 Aug;19(8):1577-85.
Impact Factor: 2.45, Citations: 9.
- ◆ Theodorou M, Samara K, Pavlakis A, Middleton N, Polyzos N, Maniadakis N. The public's and doctors' perceived role in participation in setting health care priorities in Greece. *Hellenic J Cardiol*. 2010 May-Jun;51(3):200-8.
Impact Factor: 1.343, Citations: 12.
- ◆ Theodorou M, Tsiantou V, Pavlakis A, Maniadakis N, Fragoulakis V, Pavi E, Kyriopoulos J. Factors influencing prescribing behaviour of physicians in Greece and Cyprus: results from a questionnaire based survey. *BMC Health Serv Res*. 2009 Aug 20;9:150.
Impact Factor: 1.827, Citations: 75.
- ◆ Theodoratou D, Maniadakis N, Fragoulakis V, Stamouli E. Analysis of published economic evaluations of angiotensin receptor blockers. *Hellenic J Cardiol*. 2009 Mar-Apr;50(2):105-18. Review.
Impact Factor: 1.343, Citations: 19.
- ◆ Maniadakis N, Fragoulakis V, Pectasides D, Fountzilias G. XELOX versus FOLFOX6 as an adjuvant treatment in colorectal cancer: an economic analysis. *Curr Med Res Opin*. 2009 Feb 12.
Impact Factor: 2.757, Citations: 25.
- ◆ Andrikopoulos G, Tzeis S, Maniadakis N, Mavrakis HE, Vardas PE. Cost-effectiveness of atrial fibrillation catheter ablation. *Europace*. 2009 Feb;11(2):147-51.
Impact Factor: 2.94, Citations: 17.
- ◆ Maniadakis N, Dafni U, Fragoulakis V, Grimani I, Galani E, Fragoulidi A & G Fountzilias. Economic Evaluation of Taxaned Based First Line Chemotherapy in The Treatment of Patients With Metastatic Breast Cancer in Greece: An Analysis Alongside A Multicentre Randomised Phase III Trial *Annals of Oncology*, 2009 Feb;20(2):278-85
Impact Factor: 11.855, Citations: 9.
- ◆ Maniadakis N, Fragoulakis V, Pallis A, Simou E, Georgoulas V. Economic evaluation of docetaxel-gemcitabine versus vinorelbine-cisplatin combination as front-line treatment of patients with advanced/metastatic non-small-cell lung cancer in Greece: a cost-minimization analysis *Annals of Oncology*, Volume 21, Issue 7, 1 July 2010, Pages 1462-1467
Impact Factor: 11.855, Citations: 8.
- ◆ Fountzilias G, Dafni U, Dimopoulos MA, Koutras A, Skarlos D, Papakostas P, Gogas H, Bafaloukos D, Kalogera-Fountzila A, Samantas E, Briasoulis E, Pectasides D, Maniadakis N,

Matsiakou F, Aravantinos G, Papadimitriou C, Karina M, Christodoulou C, Kosmidis P, & HP Kalofonos A Randomised Phase III Study Comparing Three Anthracycline Free Taxane Based Regimens, as First Line Chemotherapy in Metastatic Breast Cancer. A Hellenic Cooperative Oncology Group study. *Breast Cancer Research and Treatment*, 2009 May;115(1):87-99. Epub 2008 May 16.

Impact Factor: 3.626, Citations: 68.

- ◆ Maniadakis N, Kotsopoulos N, Prezerakos P & J Yfantopoulos. Health Care Services Performance Measurement: Theory, Methods and Empirical Evidence. *European Research Studies Journal*, 2009, 12(3), 151-170
Impact Factor: 0.21, Citations: 3.
- ◆ Spiraki C, Kaitelidou D, Papakonstantinou V, Prezerakos P & N Maniadakis. Health Related Quality of Life Measurement in Patients Admitted With Coronary Heart Disease and Heart Failure in A Cardiology Department of A Secondary Urban Hospital in Greece. *Hellenic Journal of Cardiology*, 2008, 49, 241-247
Impact Factor: 1.343, Citations: 29.
- ◆ Al M, Maniadakis N, EWM, Grijseels & J Matthijs. Costs and Effects of Celecoxib and NSAID-Based Treatments for Patients With Rheumatoid Arthritis and Osteoarthritis in the Netherlands. *Value Health*. 2008 Jul-Aug;11(4):589-99. Epub 2008 Jan 8.
Impact Factor: 4.235, Citations: 23.
- ◆ Maniadakis N, Kotsopoulos N, Prezerakos P & J Yfantopoulos. Measuring Intra-Hospital Clinic Efficiency and Productivity: An Application to a Greek University General Hospital. *European Research Studies Journal*, 2008, 11(1-2) 95-110
Impact Factor: 0.21, Citations: 8.
- ◆ Prezerakos P, Maniadakis N, Kaitelidou D, Kotsopoulos N & J Yfantopoulos. Measuring Across Hospital Efficiency and Productivity: The Case of Second Regional Health Authority of Attica. *European Research Studies Journal*, 2007, 10 (1-2), 83-96
Impact Factor: 0.21, Citations: 4.
- ◆ Maniadakis N, Fragoulakis V, Pallis A, Prezarakos P & V Georgoulas. Economic Evaluation of First Line Treatment in Metastatic Colorectal Cancer (MCC). Economic analysis of a multicenter, randomized, phase III trial comparing Irinotecan, Oxaliplatin, Folinic acid (FOLFOXIRI), and 5-fluorouracil (FOLFIRI) with Irinotecan, Folinic acid, and 5-fluorouracil in patients with metastatic colorectal cancer in Greece, *Journal of Current Medical Opinion* 2007, 23:9, 2251-2257
Impact Factor: 0.92, Citations: 10.
- ◆ Maniadakis N, Fragoulakis V, Pallis A, Prezarakos P & V Georgoulas. Economic Evaluation of Docetaxel/Gemcitabine versus Docetaxel as Frontline Treatment of Patients with Advanced/Metastatic Non Small Cell Lung Cancer in Greece. *Lung Cancer*, 2007, 58:2, 275-281
Impact Factor: 4.294, Citations: 8.
- ◆ Maniadakis N, Tzanakis N, Fragoulakis V, Hatzikou M & N Siafakas. Economic Evaluation of Tiotropium and Salmeterol in the Treatment of Chronic Obstructive Pulmonary Disease (COPD) in Greece. *Current Medical Research and Opinion*, 2006, 22:8, 1599-1607.
Impact Factor: 0.92, Citations: 34.

- ◆ Fountzilas G, Papakostas P, Dafni U, Makatsoris T, Karina M, Kalogera-Fountzila A, Maniadakis N, et al. Paclitaxel and Gemcitabine Vs Paclitaxel and Pegylated Liposomal Doxorubicin in Advanced Non – Nasopharyngeal Head and Neck Cancer. An Efficacy and Cost Analysis Randomized Study Conducted by the Hellenic Cooperative Oncology Group. *Annals of Oncology*, 2006, 17:10, 1560-1567
Impact Factor: 11.855, Citations: 18.
- ◆ Kaitelidou D, Zyrogianis P, Maniadakis N & L Liaropoylos. Economic Evaluation of Haemodialysis: Implications for Technology Assessment in Greece. *International Journal of Technology Assessment in Health Care*, 2005, 21:1, 40-46
Impact Factor: 1.40, Citations: 38.
- ◆ Kaitelidou D, Maniadakis N, Liaropoulos L, Ziroyannis P, Theodorou M, & O Siskou Implications of Haemodialysis Treatment on Employment Patterns and Everyday Life of Patients. *Dialysis & Transplantation*, 2005, 34:3, 138-144
Impact Factor: 0.11, Citations: 6.
- ◆ Maniadakis N, Kaitelidou D, Siskou O, Spinthouri M, Liaropoulos L, Fragoulakis B, Hatzikou M & D Alexopoulos. Economic Evaluation of Treatment Strategies for Patients Suffering Acute Myocardial Infarction in Greece. *Hellenic Journal of Cardiology*, 2005, 46, 212-221
Impact Factor: 1.343, Citations: 18.
- ◆ Foutzilas et al & N Maniadakis. Paclitaxel and Epirubicin Versus Paclitaxel and Carboplatin as First-Line Chemotherapy in Patients With Advanced Breast Cancer: A Phase III Study Conducted by the Hellenic Cooperative Oncology Group. *Annals of Oncology*, 2004, 34:1, 695-702
Impact Factor: 11.855, Citations: 65.
- ◆ Kaitelidou D, Zyrogianis P, Maniadakis N & L Liaropoylos. The Cost of Haemodialysis in Greece. *Hippokratia*, 2004, 8:2, 81-87
Impact Factor: -, Citations: 3.
- ◆ Aristides M, Weston AR, FitzGerald P, Le Reun C & N Maniadakis. Patient Preference and Willingness-To-Pay for Humalog Mix25 Relative to Humulin 30/70: A Multi-Country Application of Conjoint Analysis. *Value Health*, 2004, 7:4, 442-454
Impact Factor: 4.235, Citations: 64.
- ◆ Schiller J, Tilden D, Aristides M, Lees M, Kielhorn A, Maniadakis N & S Bhalla Retrospective Cost Analysis of Gemcitabine in Combination With Cisplatin in Non-Small Cell Lung Cancer Compared to Other Combination Therapies in Europe. *Lung Cancer*, 2004, 43:1, 101-112
Impact Factor: 4.294, Citations: 49.
- ◆ Maniadakis N & E Thanassoulis. A Cost Malmquist Productivity Index. Special Issue: DEA and its Uses in Different Countries. *European Journal of Operations Research*, 2004, 154:2, 396-409
Impact Factor: 1.01, Citations: 147.
- ◆ Aristides M, Lees M, Botwood N, McKendrick J, Stephenson DA & N Maniadakis. Economic Evaluation of Gemcitabine in the Treatment of Pancreatic Cancer in the UK. *European Journal of Health Economics*, 2003, 4:3, 216-221.
Impact Factor: 1.26, Citations: 12.

- ◆ *Liu JLY, Maniadakis N, Gray A & M Rayner. The Economic Burden of Coronary Heart Disease in the UK. Heart, 2002, 88:6, 597-603*
Impact Factor: 6.059, Citations: 214.
- ◆ *Lees M, Aristides M, Maniadakis N, McKendrick J, Botwood N & D Stephenson. Economic Evaluation of Gemcitabine Alone and in Combination With Cisplatin in the Treatment of Non-Small Cell Lung Cancer. Pharmacoeconomics, 2002, 20:5, 325-337*
Impact Factor: 3.63, Citations: 45.
- ◆ *Burke TA, Zabinski RA, Pettitt D, Maniadakis N, Maurath CJ & JL Goldstein. A Framework for Evaluating the Clinical Consequences of Initial Therapy With NSAIDs, NSAIDs Plus Gastroprotective Agents, or Celecoxib in the Treatment of Arthritis. Pharmacoeconomics, 2001, 19:S1, 33-47*
Impact Factor: 3.63, Citations: 59.
- ◆ *Pettitt D, Goldstein JL, McGuire A, Schwartz S, Burke T & N Maniadakis. Overview of the Arthritis Cost Consequence Evaluation System (ACCES): A Pharmacoeconomic Model for Celecoxib. Rheumatology, 2000, 39:2, 33-42*
Impact Factor: - , Citations: 37.
- ◆ *Maniadakis N & E Thanassoulis. Assessing Productivity Changes in UK Hospitals Reflecting Technologies and Input Prices. Applied Economics, 2000, 32, 1575-1589*
Impact Factor: 0.94, Citations: 71.
- ◆ *Maniadakis N & A Gray. Health Economics and Orthopaedics. Journal of Bone and Joint Surgery, (BR), 2000, 82:1, 2-8*
Impact Factor: 2.46, Citations: 36.
- ◆ *Maniadakis N & A Gray. The Economic Burden of Back Pain in the UK. Pain, 1999, 84:1, 95-103.*
Impact Factor: 5.445, Citations: 1319.
- ◆ *Hollingsworth B, Dawson P & N Maniadakis. Efficiency Measurement of Health Care: A Review of Non-Parametric Methods and Applications. Journal of Health Care Management Science, 1999, 2:3, 161-172*
Impact Factor: , Citations: 457.
- ◆ *Maniadakis N, Hollingsworth B & E Thanassoulis. The Impact of the Internal Market on Hospital Efficiency, Productivity and Service Quality, Special Issue: Strategic Issues in Health Care. Journal of Health Care Management Science, 1999, 2:2, 75-85.*
Impact Factor: 0.986, Citations: 95.
- ◆ *Hollingsworth B, Maniadakis N, & E Thanassoulis. Efficiency. Measured Response. Health Service Journal, 1999 Nov 25;109(5682):28-9.*
Impact Factor: 0.02, Citations: 4.

5.3 ΑΡΘΡΑ ΣΤΑ ΕΛΛΗΝΙΚΑ ΣΕ ΕΠΙΣΤΗΜΟΝΙΚΑ ΠΕΡΙΟΔΙΚΑ ΜΕ ΚΡΙΣΗ: (4)

- ◆ *Μανιαδάκης Ν, Φραγκουλάκης Β & Π Πρεζεράκος, Συγκριτικά Κόστη Νέων Τεχνολογιών Κοινωνία, Οικονομία και Υγεία, 2007, 5, 92-106*

- ◆ Κατελίδου Δ, Λιαρόπουλος Λ, Σίσκου Ο, Θεοδώρου Μ, Ζηρογιάννης Π, Μανιαδάκης Ν, Παπακωσταντίνου Β & Π Πρεζεράκος. Οι Κοινωνικές συνέπειες της αιμοκάθαρσης στην ζωή των ασθενών με χρόνια νεφρική ανεπάρκεια. Νοσηλευτική, 2007, 46, 246-255
- ◆ Μανιαδάκης Ν, Κατελίδου Δ, Σίσκου Ο, Σπινθούρη Μ, Λιαρόπουλος Λ, Φραγκουλάκης Β, Χατζίκου Μ & Δ Αλεξόπουλος. Αξιολόγηση Θεραπευτικών Στρατηγικών Διαχείρισης Ασθενών με Οξύ Έμφραγμα του Μυοκαρδίου στην Ελλάδα. Ελληνική Καρδιολογική Επιθεώρηση, 2005, 46, 212-221
- ◆ Μανιαδάκης Ν & Γ Υφαντόπουλος. Το Φαινόμενο της Προκλητής Ζήτησης Ιατρικών Υπηρεσιών. Αρχαία Ελληνικής Ιατρικής, 1996, 13:1, 1-11.

5.4 ΜΟΝΟΓΡΑΦΙΕΣ ΣΤΑ ΑΓΓΛΙΚΑ ΣΕ ΔΙΕΘΝΕΙΣ ΣΕΙΡΕΣ ΜΕ ΚΡΙΣΗ: (7)

- ◆ Maniadakis N & M Rayner. Coronary Heart Disease Statistics - Economics Supplement. British Heart Foundation. London 1998, p.1-25.
- ◆ Maniadakis N & E Thanassoulis. Changes in Productivity of a Sample of Scottish Hospitals: A Cost Index Approach. Research Paper No. 288. Research Bureau, Business School, University of Warwick, Coventry, 1998, p.1-20.
- ◆ Maniadakis N, Hollingsworth B & E Thanassoulis. The Impact of Policy Initiatives on Productive Performance. Research Paper No. 285. Research Bureau, Business School. University of Warwick, Coventry, 1998, p.1-20.
- ◆ Maniadakis N & E Thanassoulis. Indirect Productivity Measurement and its Decomposition. Research Paper No. 282. Research Bureau, Business School. University of Warwick, Coventry, 1997, p.1-19.
- ◆ Maniadakis N & L Read. A Note on Malmquist Productivity Index. Research Paper No. 278 Research Bureau, Business School. University of Warwick, Coventry, 1997, p.1-24.
- ◆ Maniadakis N & E Thanassoulis. A Cost Malmquist Type Productivity Index. Research Paper No 270. Research Bureau, Business School. University of Warwick, Coventry, 1997, p.1-22.
- ◆ Maniadakis N & E Thanassoulis. A Malmquist Index Approach to Productivity Change Measurement Allowing for Allocative Inefficiency. Research Paper No 230. Research Bureau, Business School. University of Warwick, Coventry, 1996, p.1-26.

5.5 ΚΕΦΑΛΑΙΑ ΣΕ ΕΛΛΗΝΙΚΑ ΒΙΒΛΙΑ: (3)

- ◆ Μανιαδάκης Ν & Β Φραγκουλάκης. Οικονομική Αποτίμηση Των Ενδοσκοπικών Παροχών Υγείας. Β Λιάτσικος & J Stolzenburg. Ενδοαυλική Ουρολογία. Γκιούρδας Εκδοτική, Αθήνα 2006, 446-468
- ◆ Μανιαδάκης Ν. Τα Οικονομικά της Υγείας από την Οπτική του Μάνατζερ. Κοινωνία και Υγεία. Εθνικό Ίδρυμα Ερευνών, Αθήνα 2005, σελ.75-92.

- ◆ Μανιαδάκης Ν & Β Φραγκουλάκης. Ο Ρόλος της Φαρμακοοικονομίας στον Κύκλο Ζωής του Φαρμάκου. Μ Γείτονα eds. Οικονομική Αξιολόγηση Τεχνολογιών Υγείας: Φαρμακοοικονομία και Λήψη Αποφάσεων. Εκδόσεις Πανεπιστημίου Θεσσαλίας, Βόλος 2004, σελ.125-140.

5.6 ΚΕΦΑΛΑΙΑ ΣΕ ΔΙΕΘΝΗ ΒΙΒΛΙΑ: (1)

- ◆ Maniadaakis N & A Gray. Economic evaluation, P Pynsent, J Fairbank & A Carr. Oxford Textbook in Orthopaedics and Trauma. Oxford University Press 2002, p.18-29.

5.7 ΔΗΜΟΣΙΕΥΣΕΙΣ ΠΕΡΙΛΗΨΕΩΝ ΣΕ ΤΟΜΟΥΣ ΔΙΕΘΝΩΝ ΣΥΝΕΔΡΙΩΝ: (131)

- ◆ Gourzoulidis G, Tzanetakos C, Ioannidis I, Tsapas A, Kourlaba G, Papageorgiou G, Maniadaakis N. Budget Impact Analysis of Empagliflozin for The Treatment of Patients with Type 2 Diabetes Melitus at an Increased Cardiovascular Risk in Greece. (PDB13, November 2017, ISPOR 20th Annual European Congress, Glasgow, Scotland)
- ◆ Gourzoulidis G, Kourlaba G, Petrakis D², Souglakos I³, Pentheroudakis G², Maniadaakis N. Budget Impact Analysis of Trifluridine and Tipiracil in The Treatment of Metastatic Colorectal Cancer in Greece. (PCN66, November 2017, ISPOR 20th Annual European Congress, Glasgow, Scotland)
- ◆ Solakidi A¹, Tzanetakos C¹, Bilir SP², Beaudet A³, Zervoudaki A⁴, Lamprou C⁴, Maniadaakis N. Budget-Impact of Selexipag for The Treatment of Pulmonary Arterial Hypertension (PAH) in Greece. (PRS14, November 2017, ISPOR 20th Annual European Congress, Glasgow, Scotland)
- ◆ Kourlaba G¹, Gourzoulidis G¹, Rasmussen E², Kontodimas S³, Maniadaakis N. Cost Effectiveness of Ultrasound Screening for Cancer Patients, to Detect Asymptomatic Thrombosis. PMD85, November 2017, ISPOR 20th Annual European Congress, Glasgow, Scotland)
- ◆ Solakidi A¹, Tzanetakos C¹, Maniadaakis N. Cost-Effectiveness Analysis of Apremilast for he Treatment of Active Psoriatic Arthritis in Greece (PMS45, November 2017, ISPOR 20th Annual European Congress, Glasgow, Scotland)
- ◆ Solakidi A¹, Tzanetakos C¹, Maniadaakis N. Cost-Effectiveness of Apremilast for The Treatment of Moderate to Severe Psoriasis in Greece. (PSS16, November 2017, ISPOR 20th Annual European Congress, Glasgow, Scotland)
- ◆ Gourzoulidis G¹, Tzanetakos C², Ioannidis I³, Tsapas A⁴, Kourlaba G¹, Papageorgiou G⁵, Maniadaakis N. Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Melitus at an Increased Cardiovascular Risk in Greece (PDB28, November 2017, ISPOR 20th Annual European Congress, Glasgow, Scotland)
- ◆ Vellopoulou K¹, Kourlaba G², Vagiona A³, Ntavelis A⁴, Maniadaakis N. Cost-Effectiveness of inpatient Rehabilitation Compared to Home Discharge Following Longer Stay in General or Neurological Ward, After Admission for the First Ever Stroke in Greece. PHS49, November 2017, ISPOR 20th Annual European Congress, Glasgow, Scotland)

- ◆ Gourzoulidis G¹, Kourlaba G¹, Giannoulia P², Panagiotidis P³, Maniadakis N: Cost-Effectiveness of Ponatinib in The Treatment of Patients With Accelerated or Blast Phase - Chronic Myeloid Leukemia in Greece. (PCN136, November 2017, ISPOR 20th Annual European Congress, Glasgow, Scotland)
- ◆ Gourzoulidis G¹, Kourlaba G¹, Giannoulia P², Panagiotidis P³, Maniadakis N: Cost-Effectiveness of Ponatinib in The Treatment of Patients With Acute Lymphoblastic Leukemia With Philadelphia Chromosome Positive (PH+ ALL), Suitable for Allogeneic Stem Cell Transplant, in Greece (PCN149, November 2017, ISPOR 20th Annual European Congress, Glasgow, Scotland)
- ◆ Gourzoulidis G¹, Kourlaba G¹, Giannoulia P², Panagiotidis P³, Maniadakis N: Cost-Effectiveness of Ponatinib in The Treatment of Patients With Chronic Phase Chronic Myeloid Leukemia in Greece. (PCN129, November 2017, ISPOR 20th Annual European Congress, Glasgow, Scotland)
- ◆ Solakidi A¹, Tzanetakos C¹, Beudet A², Zervoudaki A³, Lamprou C³, Maniadakis N: Cost-Effectiveness of Selexipag for the Treatment of Pulmonary Arterial Hypertension(PAH) in Greece. (PRS35, November 2017, ISPOR 20th Annual European Congress, Glasgow, Scotland)
- ◆ Gourzoulidis G¹, Vassilopoulos G², Gialama F¹, Kourlaba G¹, Diamantogiannis F³, Maniadakis N: . Economic Evaluation of Dasatinib Compared to Nilotinib as Second Line Treatment of Chronic MYELOID Leukemia in Greece. (PCN174, November 2017, ISPOR 20th Annual European Congress, Glasgow, Scotland)
- ◆ Vellopoulou K¹, Kourlaba G¹, Doupis J², Maniadakis N: Economic Evaluation of Flash Glucose Monitoring Compared to Self Monitoring for Blood Glucose for the Management of Patients Receiving Intensive Insulin With Diabetes Type 1 and Type 2 in Greece. (PMD72, November 2017, ISPOR 20th Annual European Congress, Glasgow, Scotland)
- ◆ Gourzoulidis G¹, Kourlaba G¹, Petrakis D², Souglakos I³, Pentheroudakis G², Maniadakis N: Economic Evaluation of Trifluridine and Tipiracil in the Treatment of Metastatic Colorectal Cancer in Greece. (PCN125, November 2017, ISPOR 20th Annual European Congress, Glasgow, Scotland)
- ◆ Gourzoulidis G¹, Kourlaba G², Stafylas P³, Giamouzis G⁴, Parisis J⁵, Maniadakis N: Association Between Copayment, Medication Adherence and Outcomes in the Management of Patients With Diabetes and Heart Failure. (PHS48, October 2016, ISPOR 19th Annual European Congress, Vienna, Austria)
- ◆ Mylonas C¹, Aravantinos G², Bamias A³, Kourlaba G⁴, Maniadakis N: Budget Impact Analysis of Olaparib Use in Patients BRCA – MUTATED PSROC in Greece. (PCN68, October 2016, ISPOR 19th Annual European Congress, Vienna, Austria)
- ◆ Maistreli S¹, Kourlaba G², Georgopoulos D³, Maniadakis N: Budget Impact Analysis of The Incorporation of a Computerised Temperature Engagement System in the Treatment of

Therapeutic Hypothermia in Greece. (PHS152, October 2016, ISPOR 19th Annual European Congress, Vienna, Austria)

- ◆ Gourzoulidis G¹, Kourlaba G², Kakisis J³, Matsagkas M⁴, Giannakoulas G⁵, Gourgoulialis K⁶, Vassilakopoulos T⁷, Arzoumanidou D⁸, Maniadakis N: Cost Effectiveness Analysis of Rivaroxaban for Treatment of Deep Vein Thrombosis and Pulmonary Embolism in Greece. (PRS32, October 2016, ISPOR 19th Annual European Congress, Vienna, Austria)
- ◆ Tzanetakos C¹, Bargiota A², Kourlaba G³, Maniadakis N: . Cost-Effectiveness of Exenatide Once Weekly Versus Insulin Glargine and Liraglutide for the Treatment of Type 2 Diabetes in Greece. (PDB41, October 2016, ISPOR 19th Annual European Congress, Vienna, Austria)
- ◆ Tzanetakos C¹, Kourlaba G², Chatzikou M³, Antoniou C⁴, Ioannidis D⁵, Lefaki I⁶, Petridis A⁷, Rigopoulos D⁸, Roussaki-Schulze A⁹, Sotiriadis D¹⁰, Maniadakis N: Cost-Effectiveness of Secukinumab Compared With Ustekinumab and Etanercept for The Treatment of Moderate to Severe Psoriasis in Greece. (PSS42, October 2016, ISPOR 19th Annual European Congress, Vienna, Austria)
- ◆ Stafylas P¹, Farmakis D², Kourlaba G³, Giamouzis G⁴, Chatzikou M⁵, Kossiva E⁶, Maniadakis N, Parissis J⁸ Cost-Utility Analysis of Sacutibril/Valsartan for the Treatment of Chronic Heart Failure in Greece. (PCV102, October 2016, ISPOR 19th Annual European Congress, Vienna, Austria)
- ◆ Solakidi A¹, Kourlaba G¹, Kontovinis L², Koutsoukos K³, Bournakis E⁴, Boutis A⁵, Syrios J⁶, Tzouvaras A⁷, Michailidi C⁸, Kalogeropoulou M⁸, Maniadakis N: Economic Evaluation of Everolimus as Second-Line Treatment of Metastatic Renal Carcinoma in Greece. (PCN132, October 2016, ISPOR 19th Annual European Congress, Vienna, Austria)
- ◆ Mylonas C¹, Aravantinos G², Bamias A³, Kourlaba G⁴, Maniadakis N: Economic Evaluation of Olaparib in Patients With BRCA – Mutated PSROC in Greece. (PCN134, October 2016, ISPOR 19th Annual European Congress, Vienna, Austria)
- ◆ Mylonas C¹, Kourlaba G², Vernadaki A³, Kakouros M³, Maniadakis N: Economic Evaluation of Paritaprevir/Ritonavir/Ombitasvir (PrO) for Patients With Genotype 4 HCV in Greece. (Pin63, October 2016, ISPOR 19th Annual European Congress, Vienna, Austria)
- ◆ Mylonas C¹, Kourlaba G², Vernadaki A³, Kakouros M³, Maniadakis N: Economic Evaluation of Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir (PrOD) for Patients With Genotype 1A HCV in Greece. (Pin59, October 2016, ISPOR 19th Annual European Congress, Vienna, Austria)
- ◆ Mylonas C¹, Kourlaba G², Vernadaki A³, Kakouros M³, Maniadakis N: Economic Evaluation of Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir (PrOD) for Patients With Genotype 1B HCV in Greece. (Pin61, October 2016, ISPOR 19th Annual European Congress, Vienna, Austria)

- ◆ Mylonas C¹, Kourlaba G², Skroumpelos A³, Maniadakis N: Economic Evaluation of Pertuzumab Neoadjuvant Treatment for Patients With Locally Advanced, inflammatory, or Early Stage HER2-Positive Breast Cancer in Greece. (PCN148, October 2016, ISPOR 19th Annual European Congress, Vienna, Austria)
- ◆ Maniadakis N , Kourlaba G², Zavali M¹, Zampoulakis D³, Kourkouni E², Mylonas C¹ Factors Affecting Pharmaceutical Expenditures: A Systematic Review & Economic Modelling for Greece. (PHP103, October 2016, ISPOR 19th Annual European Congress, Vienna, Austria)
- ◆ Maistreli S¹, Kourlaba G², Tzanetakos C², Trontzas P³, Maniadakis N: The Clinical and Pharmacoeconomic Value of Febuxostat for the Treatment of Persistent Hyperuricaemia: A Systematic Literature Review. (PMS45, October 2016, ISPOR 19th Annual European Congress, Vienna, Austria)
- ◆ Kourlaba G¹, Gialama F², Vellopoulou K¹, Tsioufis K³, Maniadakis N: The Clinical Value of Olmesartan for the Treatment of Hypertensive Patients: A Systematic Review. (PCV19, October 2016, ISPOR 19th Annual European Congress, Vienna, Austria)
- ◆ Maistreli S¹, Gourzoulidis G², Vellopoulou K³, Kourlaba G³, Maniadakis N: The Clinical, Functional and Economic Benefits of Physical Rehabilitation: A Systematic Review. (PHS165, October 2016, ISPOR 19th Annual European Congress, Vienna, Austria)
- ◆ Stafylas P¹, Farmakis D², Kourlaba G³, Aletras V⁴, Giamouzis G⁵, Tsarouhas K⁵, Zouka M⁶, Maniadakis N , Parissis J⁸ The Economic Burden of Heart Failure in Greece From a Social Security System Perspective. (PCV60, October 2016, ISPOR 19th Annual European Congress, Vienna, Austria)
- ◆ Gialama F¹, Kourlaba G², Gourzoulidis G¹, Tsioufis K³, Maniadakis N: The Economic Value of Olmesartan for The Treatment of Hypertensive Patients: A Systematic Review. (PCV98, October 2016, ISPOR 19th Annual European Congress, Vienna, Austria)
- ◆ Brixner D, Maniadakis N, Kaló Z, Hu S, Johnston A, Shen J, Wijaya KE. Application of multi-criteria decision analysis (MCDA) scoring as an HTA methodology for off-patent pharmaceuticals (OPP) in emerging markets. (PHP4, September 2016, ISPOR 7th Asia-Pacific Conference, Singapore)
- ◆ Vellopoulou K, Kourlaba G, Maniadakis N, Vardas P. A literature review to evaluate the pharmacoeconomic value of ranolazine for the treatment of symptomatic chronic stable angina. (PCV124, November 2015, ISPOR 18th Annual European Congress, Milan, Italy)
- ◆ Stafylas P, Mavrodi A, Kourlaba G, Maniadakis N. 8c.06: Cost-Effectiveness of Two Single-Pill Triple Antihypertensive Therapies Based on the Ambulatory Blood Pressure Measurements. J Hypertens 2015;33 Suppl 1:e111.
- ◆ Tzanetakos C, Vassilopoulos D, Kourlaba G, Christou P, Maniadakis N. Budget impact analysis of certolizumab pegol for the treatment of active psoriatic arthritis in Greece. (PMS29, November 2015, ISPOR 18th Annual European Congress, Milan, Italy)

- ◆ Relakis I, Patrikos D, Kourlaba G, Christou P, Maniadakis N. Budget impact analysis of certolizumab pegol in the treatment of axial spondyloarthritis in Greece. (PMS32, November 2015, ISPOR 18th Annual European Congress, Milan, Italy)
- ◆ Kourlaba G, Gourzoulidis G, Aravantinos G, Athanasiadis I, Lyman GH, Villa G, Papagiannopoulou V, Tritaki G, Maniadakis N. Cost-effectiveness analysis of granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced febrile neutropenia in patients with breast cancer in Greece. (PCN149, November 2015, ISPOR 18th Annual European Congress, Milan, Italy)
- ◆ Gourzoulidis G, Kourlaba G, Apostolidis J, Lyman GH, Villa G, Papagiannopoulou V, Tritaki G, Maniadakis N. Cost-effectiveness analysis of granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced febrile neutropenia in patients with non-hodgkin's lymphoma in Greece. (PCN156, November 2015, ISPOR 18th Annual European Congress, Milan, Italy)
- ◆ Kourlaba G, Tzanetakos C, Datseris J, Rouvas A, Arzoumanidou D, Maniadakis N. Cost-effectiveness analysis of intravitreal aflibercept in the treatment of neovascular age-related macular degeneration in Greece. (PSS33, November 2015, ISPOR 18th Annual European Congress, Milan, Italy)
- ◆ Tzanetakos C, Tentolouris N, Kourlaba G, Maniadakis N. Cost-effectiveness of dapagliflozin as add-on to metformin for the treatment of type 2 diabetes in Greece. (PDB55, November 2015, ISPOR 18th Annual European Congress, Milan, Italy)
- ◆ Tzanetakos C, Vassilopoulos D, Kourlaba G, Christou P, Maniadakis N. Cost-utility analysis of certolizumab pegol for the treatment of active psoriatic arthritis IN GREECE. (PMS74, November 2015, ISPOR 18th Annual European Congress, Milan, Italy)
- ◆ Relakis I, Patrikos D, Kourlaba G, Christou P, Maniadakis N. Cost-utility of certolizumab pegol for the treatment of axial spondyloarthritis in Greece. (PMS60, November 2015, ISPOR 18th Annual European Congress, Milan, Italy)
- ◆ Kourlaba G, Relakis J, Mahon R, Kalogeropoulou M, Pantelopoulou G, Kousidou O, Maniadakis N. Cost-utility of ranibizumab versus aflibercept for treating visual impairment due to diabetic macular edema in Greece. (PSS44, November 2015, ISPOR 18th Annual European Congress, Milan, Italy)
- ◆ Kourlaba G, Vlachopoulos C, Parissis J, Kanakakis J, Gourzoulidis G, Maniadakis N. Cost-utility of ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Greece. (PCV122, November 2015, ISPOR 18th Annual European Congress, Milan, Italy)
- ◆ Kourlaba G, Gourzoulidis G, Tsioufis K, Andrikopoulos G, Beletsi A, Maniadakis N. Economic evaluation of trimetazidine in the management of chronic stable angina in Greece. (PCV100, November 2015, ISPOR 18th Annual European Congress, Milan, Italy)
- ◆ Kourlaba G, Chatzikou M, Pantelopoulou G, Maniadakis N. Health and economic outcomes related to delay between medical indication and treatment with ranibizumab in age-related macular degeneration in Greece. (PSS46, November 2015, ISPOR 18th Annual European Congress, Milan, Italy)

- ◆ Cristino J, Diel I, Finek J, Perez Encinas M, Maniadakis N, Ikenberg R, Campos Tapias I, Jandova P, Zahn DP, Moser C, Bolognese L, Tritaki G, Gatta F, Hechmati G The clinical and economic burden of skeletal related events in austria, czech republic, Germany, Greece, Italy, Spain and Switzerland: a comparison between the use of denosumab and zoledronic acid in patients with breast cancer and bone metastases. (PCN299, November 2015, ISPOR 18th Annual European Congress, Milan, Italy)
- ◆ Cristino J, Finek J, Maniadakis N, Perez Encinas M, Ikenberg R, Campos Tapias I, Jandova P, Zahn DP, Moser C, Bolognese L, Tritaki G, Gatta F, Hechmati G. The clinical and economic burden of skeletal related events in austria, czech republic, Germany, Greece, Italy, Spain and Switzerland: a comparison between the use of denosumab and zoledronic acid in patients with prostate cancer and bone metastases. (PCN298, November 2015, ISPOR 18th Annual European Congress, Milan, Italy)
- ◆ Fanourgiakis JA, Simantirakis E, Kanoupakis E, Chrysostomakis S, Maniadakis N, Kourlamba G, Vardas P. Annual medication cost attributed to each kind of treatment of patients subjected to crmds implantation . (PCV62, May 2015, ISPOR 20th Annual International Meeting, Philadelphia, PA, USA)
- ◆ Fanourgiakis JA, Simantirakis E, Kanoupakis E, Chrysostomakis S, Maniadakis N, Kourlamba G, Vardas P. Cost attributed to productivity loss in patients subjected to pacemaker (PM) and implantable cardioverter-defibrillator (ICD) implantation .(PMD53, May 2015, ISPOR 20th Annual International Meeting, Philadelphia, PA, USA)
- ◆ Tzanetakos C, Maniadakis N, Kourlaba G, Tzioufas A, Goules A, Theodoratou T, Christou P Budget impact analysis of certolizumab pegol in the management of patients with moderate-to-severe active rheumatoid arthritis in Greece. (PMS15, November 2014, ISPOR 17th Annual European Congress, Amsterdam, The Netherlands)
- ◆ Kourlaba G, Boletis I, Goumenos D, Iatrou C, Papagiannopoulou V, Tritaki G, Maniadakis N Cost consequence analysis of darbepoetin alfa for the treatment of anemia due to chronic kidney disease (CKD) in Greece. (PUK15, November 2014, ISPOR 17th Annual European Congress, Amsterdam, The Netherlands)
- ◆ Tzanetakos C, Melidonis A, Verras C, Kourlaba G, Maniadakis N.Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled type 2 diabetes on oral antidiabetic drugs in Greece .(PDB74, November 2014, ISPOR 17th Annual European Congress, Amsterdam, The Netherlands)
- ◆ Kourlaba G, Boukovinas I, Saridaki Z, Papagiannopoulou V, Tritaki G, Maniadakis N. Cost -effectiveness analysis of PANITUMUMAB+MFOLFOX over BEVACIZUMAB+MFOLFOX as a first-line treatment for metastatic colorectal cancer patients with wild-type ras Greece.(PCN110, November 2014, ISPOR 17th Annual European Congress, Amsterdam, The Netherlands)
- ◆ Kourlaba G, Palaka E, Papagiannopoulou V, Maniadakis N.Cost-effectiveness and cost-utility of granulocyte colony-stimulating factors in the primary prophylaxis of chemotherapy induced febrile neutropenia (FN) in breast cancer patients in Greece: a comparative analysis .(PCN111, November 2014, ISPOR 17th Annual European Congress, Amsterdam, The Netherlands)
- ◆ Mylonas C, Kourlaba G, Fountzilias G, Skroumpelos A, Maniadakis N.Cost-minimization analysis of trastuzumab intravenous versus trastuzumab subcutaneous for the treatment of patients with HER2+ early breast cancer and metastatic breast cancer in Greece

(PCN151, November 2014, ISPOR 17th Annual European Congress, Amsterdam, The Netherlands)

- ◆ Tzanetakos C, Maniadakis N, Kourlaba G, Tzioufas A, Goules A, Theodoratou T, Christou P .Cost-utility analysis of certolizumab pegol plus methotrexate for the treatment of moderate-to-severe active rheumatoid arthritis in Greece .(PMS54, November 2014, ISPOR 17th Annual European Congress, Amsterdam, The Netherlands)
- ◆ Mylonas C, Kourlaba G, Berberian K, Maniadakis N .Economic evaluation of ferric carboxymaltose in patients with chronic heart failure and iron deficiency: an analysis for Greece based on FAIR-HF TRIAL .(PCV80, November 2014, ISPOR 17th Annual European Congress, Amsterdam, The Netherlands)
- ◆ Fragoulakis V, Papakostas P, Pentheroudakis G, Dervenis C, Maniadakis N .Economic evaluation of nab-paclitaxel plus gemcitabine versus gemcitabine alone for the management of metastatic pancreatic cancer in Greece .(PCN105, November 2014, ISPOR 17th Annual European Congress, Amsterdam, The Netherlands)
- ◆ Relakis J, Paparrigopoulos T, Kourlaba G, Maniadakis N .Economic evaluation of nalmefene for the treatment of alcohol dependence in Greece .(PMH27, November 2014, ISPOR 17th Annual European Congress, Amsterdam, The Netherlands)
- ◆ Stafylas P, Mavrodi A, Kourlaba G, Hatzikou M, Rombopoulos G, Maniadakis N .Economic evaluation of valsartan versus olmesartan addition to amlodipine and hydrochlorothiazide single-pill triple antihypertensive therapy .(PCV99, November 2014, ISPOR 17th Annual European Congress, Amsterdam, The Netherlands) pdf available
- ◆ Relakis J, Kourlaba G, Maniadakis N .Simvastatin plus fenofibrate as a fixed dose combination in the treatment of mixed dyslipidaemia in Greece: Budget impact analysis (PCV41, November 2014, ISPOR 17th Annual European Congress, Amsterdam, The Netherlands)
- ◆ Simantirakis E, Fanourgiakis J, Kanoupakis E, Chrysostomakis S, Maniadakis N, Kourlaba G, Vardas P .Association between baseline socio-demographic and clinical characteristics and total annual cost of patients subjected to CRMDs implantation .(PCV44, September 2014, ISPOR 6th Asia-Pacific Conference, Beijing, China)
- ◆ Fragoulakis V, Pescott C, Maniadakis N .Economic evaluation of in-vitro fertilization as assisted reproductive technique in management of infertility in the netherlands: a cost-effectiveness model based on a long down-regulation protocol .(PIH32, May 2014, ISPOR 19th Annual International Meeting, Palais des Congrès de Montréal)
- ◆ Fanourgiakis J, Simantirakis E, Kanoupakis E, Chrysostomakis S, Maniadakis N, Kourlaba G, Vardas P .Follow up cost of patients subjected to crmd in Greece.(PCV97, May 2014, ISPOR 19th Annual International Meeting, Palais des Congrès de Montréal)
- ◆ Fanourgiakis J, Simantirakis E, Kanoupakis E, Chrysostomakis S, Maniadakis N, Kourlaba G, Vardas P .Procedure (implantation) cost and total hospitalization cost of patients subjected to cardiac rhythm management devices implantation: results from a single tertiary centre. (PCV99, May 2014, ISPOR 19th Annual International Meeting, Palais des Congrès de Montréal) pdf available

- ◆ Pappa V, Fragoulakis V, Maniadakis N, Tsatalas C, Zikos P, Meletis J, Anagnostopoulos N, Anagnostopoulos A. Safety and tolerability of azacitidine in patients with intermediate-2 and high risk myelodysplastic syndromes in Greece: a retrospective chart review study for the daily practise .(PSY12, May 2014, ISPOR 19th Annual International Meeting, Palais des Congrès de Montréal)
- ◆ Pappa V, Fragoulakis V, Maniadakis N, Briasoulis E, Tsionos K, Kioumi A, Vervesou E, Symeonidis A .The overall response rate of azacitidine in patients with intermediate-2 and high risk myelodysplastic syndromes: a retrospective chart review study from Greece .(PSY2, May 2014, ISPOR 19th Annual International Meeting, Palais des Congrès de Montréal)
- ◆ Maniadakis N, Kourlaba G , Kapaki V, Damianidi L. A systematic review of the effectiveness of taxes in preventing obesity trends. (PSY80, November 2013, ISPOR 16th Annual European Congress, The Convention Centre Dublin)
- ◆ Gialama F, Maniadakis N. Comprehensive overview: efficacy, tolerability and cost- effectiveness of Irbesartan. (PCV87, November 2013, ISPOR 16th Annual European Congress, The Convention Centre Dublin)
- ◆ Kourlaba G, Parissis J, Karavidas A, Beletsi A, Milonas C, Maniadakis N .Economic evaluation of ivabradine in chronic heart failure in Greece. (PCV72, November 2013, ISPOR 16th Annual European Congress, The Convention Centre Dublin)
- ◆ Maniadakis N, Kourlaba G, Shen J, Holtorf AP, Kalo Z. Mapping and analysing pharmaceutical policy settings worldwide. (PHP201, November 2013, ISPOR 16th Annual European Congress, The Convention Centre Dublin)
- ◆ Maniadakis N, Kourlaba G, Shen J, Holtorf AP, Kalo Z. Pharmaceutical policies, regulation and efficiency. (PR2, November 2013, ISPOR 16th Annual European Congress, The Convention Centre Dublin)
- ◆ Relakis J, Maniadakis N, Kourlaba G, Shen J, Holtorf AP .Systematic review on the impacts of strict pharmaceutical price controls .(PHP199, November 2013, ISPOR 16th Annual European Congress, The Convention Centre Dublin)
- ◆ Fragoulakis V, Stamoulis K, Grouzi E, Maniadakis N. The cost of producing a unit of blood in hospitals: a nationwide economic analysis for the case of Greece .(PSY39, November 2013, ISPOR 16th Annual European Congress, The Convention Centre Dublin)
- ◆ Kourlaba G, Relakis J, Kontodimas S, Holm MV, Maniadakis N .The humanistic and economic burden of venous thromboembolism in cancer patients: a systematic review .(PCN67, November 2013, ISPOR 16th Annual European Congress, The Convention Centre Dublin)
- ◆ Kourlaba G, Milonas C, Kontodimas S, Holm MV, Maniadakis N .The humanistic and economic burden of venous thromboembolism in pregnant women: a systematic review .(PCV30, November 2013, ISPOR 16th Annual European Congress, The Convention Centre Dublin)
- ◆ Asukai Y, Maniadakis N, Carcedo D, Lukac M, Evers T .Cost-effectiveness of rivaroxaban for the prevention of stroke in patients with non-valvular atrial fibrillation – a multinational study .(PCV79, May 2013, ISPOR 18th Annual International Meeting, New Orleans, LA, USA)

- ◆ Fragoulakis V, Maniadakis N .Cost benefit analysis on the long term effects of in vitro fertilization (IVF) in Greece: an analysis based on a lifetime model .(PIH17, November 2012, ISPOR 15th Annual European Congress, Berlin, Germany)
- ◆ Holtorf AP, Rinde H, Maniadakis N .Drug shortages around the world and the underlying reasons .(PHP142, November 2012, ISPOR 15th Annual European Congress, Berlin, Germany) pdf available
- ◆ Stafylas P, Kourlaba G, Hatzikou M, Georgiopoulos D, Maniadakis N .Economic evaluation of a single pill triples antihypertensive therapy with valsartan, amlodipine, and hydrochlorothiazide against its dual components in Greece . (PCV53, November 2012, ISPOR 15th Annual European Congress, Berlin, Germany) pdf available
- ◆ Stafylas P, Kourlaba G, Georgiopoulos D, Hatzikou M, Maniadakis N .Economic evaluation of a single-pill triple combination with valsartan, amlodipine and hydrochlorothiazide against its dual components in greece. The generic substitution case (PCV44, November 2012, ISPOR 15th Annual European Congress, Berlin, Germany)
- ◆ Kourlaba G, Maniadakis N, Andrikopoulos G, Vardas P, Llyod A, Asukai Y, Evers T .Economic evaluation of rivaroxaban in stroke prevention among patients with atrial fibrillation in Greece .(PCV49, November 2012, ISPOR 15th Annual European Congress, Berlin, Germany)
- ◆ Kourlaba G, Maniadakis N, Giannoukas A, Katsamouris A, Katsenis K, Lazarides M, Matsagas M, Lowin J, McLeod EJ, Bamber L .Economic evaluation of rivaroxaban in the treatment of deep vein thrombosis in Greece .(PCV54, November 2012, ISPOR 15th Annual European Congress, Berlin, Germany)
- ◆ Milonas C, Milonas A, Kouvelas D, Dokios G, Maniadakis N .The benefits of using OTC: a systematic literature review . (PHP85, November 2012, ISPOR 15th Annual European Congress, Berlin, Germany)
- ◆ Milonas C, Milonas A, Kouvelas D, Dokios G, Maniadakis N .The economic health value from RX to OTC switch in Greece .(PHP84, November 2012, ISPOR 15th Annual European Congress, Berlin, Germany)
- ◆ Milonas A, Milonas C, Dokios G, Kouvelas D, Maniadakis N .The OTC policy in Europe and GREECE .(PHP83, November 2012, ISPOR 15th Annual European Congress, Berlin, Germany)
- ◆ Kourlaba G, Maniadakis N, Mougiakos T, Chatzimanolis I .Economic evaluation of agomelatine for major depressive disorders in the Greek setting .(PMH33, June 2012, ISPOR 17th Annual International Meeting, Washington, D.C., USA)
- ◆ Fragoulakis V, Kourlaba G, Maniadakis N .Economic evaluation of lenalidomide in the management of previously treated multiple myeloma (PTMM) patients in Greece. (PSY35, June 2012, ISPOR 17th Annual International Meeting, Washington, D.C., USA)
- ◆ Fragoulakis V, Iatrou C, Maniadakis N .Economic evaluation of darbepoetin alfa in the management of end stage renal disease (ESRD) patients with anemia in the Greek NHS setting.(PSY35, November 2011, ISPOR 14th Annual European Congress, Madrid, Spain) pdf available

- ◆ Fragoulakis V, Tarlatzis B, Mastrominas M, Maniadakis N.Economic evaluation of recombinant human FSH in comparison with urinary hmg in assisted reproduction in the GREEK setting.(PDB42, November 2011, ISPOR 14th Annual European Congress, Madrid, Spain) pdf available
- ◆ Maniadakis N, Fragoulakis V, Athanasakis K, Kyriopoulos J. Economic evaluation of dronedarone in treatment of atrial fibrillation in Greece. (PCV86, November 2010, ISPOR 13th Annual European Congress, Prague, Czech Republic)
- ◆ Maniadakis N, Athanasakis K, Fragoulakis V, Tsiantou V, Kyriopoulos J. Economic evaluation of ranibizumab in the treatment of age-related macular degeneration in Greece .(PSS12, November 2010, ISPOR 13th Annual European Congress, Prague, Czech Republic) pdf available
- ◆ Maniadakis N, Fragoulakis V, Pectasides D, Foutzilias G .Economic evaluation in the postoperative management of colorectal cancer patients in Greece .(PCN47, November 2008, ISPOR 11th Annual European Congress , Athens, Greece)
- ◆ Maniadakis N, Fragoulakis V, Papagiannopoulou V, Yfantopoulos I, Economic evaluation of irbesartan in Greece . (PCV79, November 2008, ISPOR 11th Annual European Congress, Athens, Greece)
- ◆ Raikou M, Theodoratou Th, Maniadakis N .Meta-analysis of the efficacy of telmisartan on blood pressure in patients with mild to moderate hypertension .(PCV4, October 2007, ISPOR Tenth Annual European Congress, Dublin, Ireland)
- ◆ Theodoratou Th, Maniadakis N, Fragoulakis V, Hatzikou M .Angiotensin ii receptor blockers (ARBS) for mild to moderate hypertension: a literature review .(PCV72, October 2006, ISPOR Ninth Annual European Congress, Copenhagen, Denmark)
- ◆ Angeli A, Maniadakis N .Cost analysis of health care resource utilization during treatment for respiratory track infections (RTIS) with telithromycin or clarithromycin or AMOXICILLIN/CLAVULANIC ACID IN Greece.(PRS13, November 2005, ISPOR Eighth European Congress, Florence, Italy)
- ◆ Maniadakis N, Tzanakis N, Geitona M, Fragoulakis V, Hatzikou M, Siafakas N .Economic evaluation of tiotropium and salmeterol in the treatment of copd in Greece.(PRS6, November 2005, ISPOR Eighth European Congress, Florence, Italy)
- ◆ Maniadakis N, Hatzikou M, Kaitelidou D, Spinthouri M, Siskou O, Fragoulakis B, Liappis T, Liaropoulos L .An economic evaluation of alteplase, reteplase and tenecteplase in treatment of acute mi in Greece .(PCV67, November 2003, ISPOR Sixth Annual European Congress, Barcelona, Spain)
- ◆ Maniadakis N, Hatzikou M, liappis T, Kaitelidou D, Spinthouri M, Siskou O, Fragoulakis B, Liaropoulos L .An economic evaluation of treatments for acute mi in greece in elderly and late treatment patients . (PCV71, November 2003, ISPOR Sixth Annual European Congress, Barcelona, Spain) pdf available
- ◆ Maniadakis N, Fragoulakis B, Liapis M, Hatzikou M . An evaluation of the costs associated with acute mi treatment in and out of hospitals in Greece .(PCV43, November 2003, ISPOR Sixth Annual European Congress, Barcelona, Spain) pdf available

- ◆ Bhalla S, Kielhorn A, Maniadakis N, Eli Lilly, Windlesham, Surrey, United Kingdom .Is there difference between gemcitabine based nsclc treatment and other platinum based combinations for response rates and toxicity? (PCN20, November 2002, ISPOR Fifth Annual European Congress, Rotterdam, The Netherlands)
- ◆ Aristides M, Weston A, FitzGerald P, LeReun C, Schulz M, Maniadakis N, Kielhorn A, Patient preference and willingness-to-pay in five European countries for Humalog mix25 compared to humulin 30/70 for the treatment of type 2 diabetes .(WD3, November 2002, ISPOR Fifth Annual European Congress, Rotterdam, The Netherlands) pdf available
- ◆ Kielhorn A, Maniadakis N, Aristides M, Lees M, Tilden D .Retrospective cost analysis of gemzar (tm) in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in Germany. (PCN4, May 2002, ISPOR Seven Annual International Meeting, Arlington, VA, USA)
- ◆ Jansen R, Clausen JO, Maniadakis N, Kielhorn A, Brandt A. An assessment of the cost-effectiveness of pioglitazone (actos?, takeda) in type 2 diabetes mellitus in Denmark, (PDG14, November 2001, ISPOR Fourth Annual European Congress, Cannes, France)
- ◆ Maniadakis N, Sacristan J, Reviriego J, Hart W, Jansen R, Kielhorn A, Brandt A .An economic evaluation of combination therapy with pioglitazone in type 2 diabetes mellitus from a Spanish health-care perspective .(PDG3, November 2001, ISPOR Fourth Annual European Congress, Cannes, France)
- ◆ Henriksson F, Brandt A, Thomander L, Kielhorn A, Jansen R, Maniadakis N .Cost-effectiveness of pioglitazone in the management of type 2 diabetes mellitus in SwedenN .(PDG6, November 2001, ISPOR Fourth Annual European Congress, Cannes, France)
- ◆ Brandt A, Frislid K, Jansen R, Maniadakis N, Kielhorn A. Health and economic outcomes of a new oral diabetes drug, pioglitazone), in the management of type 2 diabetes mellitus in Norway. (PDG11, November 2001, ISPOR Fourth Annual European Congress, Cannes, France)
- ◆ Maniadakis N, Kielhorn A, Heikkinen K, Brandt A, Jansen R. The outcomes of long-term treatment of a new oral diabetes drug pioglitazone (ACTOS ?) In the management of type 2 diabetes in Finland. (PDG1, November 2001, ISPOR Fourth Annual European Congress, Cannes, France)
- ◆ McKendrick J, Botwood N, Aristides M, Lees M, Maniadakis N, Wein W, Stephenson D. Economic evaluation of GEMZAR and best supportive care (BSC) relative to best supportive care alone in the treatment of non-small cell lung (NSCLC) cancer in the UK. (PCN7, May 2001, ISPOR Sixth Annual International Meeting, Arlington, VA, USA)
- ◆ Stephenson D, Botwood N, McKendrick J, Aristides M, Lees M, Maniadakis N, Wein W. Economic evaluation of GEMZAR in the treatment of pancreatic cancer in the UK .(PCN8, May 2001, ISPOR Sixth Annual International Meeting, Arlington, VA, USA)
- ◆ Botwood N, McKendrick J, Aristides M, Lees M, Maniadakis N, Wein W, Stephenson D . Economic evaluation of GEMZAR/CISPLATIN relative to other cisplatin based treatments for non-small cell lung (NSCLC) cancer in the UK .(CN4, May 2001, ISPOR Sixth Annual International Meeting, Arlington, VA, USA)

- ◆ Lees M, Aristides M, Botwood N, McKendrick J, Maniadakis N, Wein W, Stephenson D. Economic evaluation of GEMZAR/CISPLATIN relative to other new agents for non-small cell lung cancer (NSCLC) in the UK. (PCN9, May 2001, ISPOR Sixth Annual International Meeting, Arlington, VA, USA)
- ◆ Stephenson D, Botwood N, McKendrick J, Aristides M, Lees M, Maniadakis N & W Wein. GEMZAR in the treatment of pancreatic cancer in the UK: An economic evaluation European Journal of Cancer, 2001, 37(6) p.233-233(1)
- ◆ Botwood N, McKendrick J, Aristides M, Lees M, Maniadakis N, Wein W & D Stephenson. Economic evaluation of GEMZAR/CISPLATIN relative to other cisplatin based treatments for non small cell lung (NSCLC) cancer in the UK. European Journal of Cancer, 2001, 37(6) p.233-233(1)
- ◆ Emery P, Lamb Y, Maniadakis N, Burke T, & G Robinson Upper Gastrointestinal Tolerability of Celecoxib, A Cox-2 Inhibitor, Compared to Diclofenac Among Patients With Rheumatoid and Osteoarthritis. Arthritis and Rheumatism 2000.

6. ΣΥΜΜΕΤΟΧΗ ΣΕ ΣΥΝΕΔΡΙΑ ΚΑΙ ΕΠΙΤΡΟΠΕΣ

6.1 ΜΕΛΟΣ ΣΕ ΕΠΙΤΡΟΠΕΣ ΕΜΠΕΙΡΟΓΝΩΜΟΝΩΝ:

- ◆ **National Expert**, 2014 – 2016. Expert Group on Health Systems Performance Assessment, European Commission
- ◆ **Scientific Coordinator, 2010 - Present**, Health Policy Unit, European Society of Cardiology, Brussels, Belgium
- ◆ **Elected Member of Board**, 2013 – 2015. European Health Management Association (EHMA) Brussels, Belgium
- ◆ **Μέλος**, 2013 -2014, Εθνικό Συμβούλιο Δημόσιας Υγείας, Υπουργείο Υγείας
- ◆ **Μέλος**, 2011 -2012, Ανεξάρτητη Επιτροπή Εμπειρογνωμόνων για την Μεταρρύθμιση του Συστήματος Υγείας, Υπουργείο Υγείας – Τρόικα
- ◆ **Πρόεδρος Επιτροπής**. 2010-2011. Επιτροπή Ανάπτυξης DRGs στη Ελλάδα, Υπουργείο Υγείας
- ◆ **National Expert**, 2009, European Commission, Directorate General Enterprise and Industry, Unit F3 - Cosmetics and Medical Devices
- ◆ **Εμπειρογνώμονας**, 2008, Ευρωπαϊκή Μελέτη της Υγείας Ελληνικού Πληθυσμού, Εθνική Στατική Υπηρεσία της Ελλάδος και Eurostat, Αθήνα
- ◆ **Μέλος**, 2008, Υπουργείο Υγείας και Κοινωνικής Αλληλεγγύης, Επιστημονική Επιτροπή για την Αξιολόγηση Εθνικού Σχεδίου Δράσης Δημόσιας Υγείας, Αθήνα
- ◆ **Αντιπρόεδρος**, 2006 - , Ελληνική Εταιρεία Διοίκησης Υπηρεσιών Υγείας Αθήνα

- ♦ **Μέλος**, 2006, Επιτροπή Αξιολόγησης Υπηρεσιών Υγείας, Κέντρο Ελέγχου και Πρόληψης Νοσημάτων (ΚΕΕΛΠΝΟ), Υπουργείο Υγείας και Κοινωνικής Αλληλεγγύης, Αθήνα
- ♦ **Μέλος**, 2005, Επιτροπή Παρασκευής Νόμου 3329/2005, Εθνικό Σύστημα Υγείας και Κοινωνικής Αλληλεγγύης και Λοιπές Διατάξεις, Υπουργείο Υγείας και Κοινωνικής Αλληλεγγύης, Αθήνα

6.2 ΣΥΜΜΕΤΟΧΗ ΣΕ ΣΥΝΕΔΡΙΑ: 2009 -

- ♦ **Μέλος Οργανωτικής ή Επιστημονικής Επιτροπής: (12)**
- ♦ **Συντονιστής Τραπεζών: (21)**
- ♦ **Προσκεκλημένος Ομιλητής την Ελλάδα (284)**
- ♦ **Προσκεκλημένος Ομιλητής στο Εξωτερικό (89)**
- ♦ **Παρουσιάσεις Εργασιών σε Διεθνή Συνέδρια (36)**